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Historical aspects of glucocorticoids 
Glucocorticoids (GCs) constitute a well-characterized class of steroid hormones that are 
produced by the adrenal glands. The name glucocorticoid derives from their role in the 
regulation of glucose metabolism (‘gluco-‘), their synthesis in the adrenal cortex (‘-cortic-
‘) and their steroidal structure (‘-oid’). They were first isolated in 1936 and in 1948 they 
were first used clinically as anti-inflammatory drugs in the treatment of rheumatoid 
arthritis patients [1]. The importance of the discovery of GCs culminated in a Nobel Prize 
in Physiology or Medicine for Edward Kendall, Tadeus Reichstein and Philip Hench in 
1950 for their work related to the structure and physiological effects of these steroid 
hormones [2, 3]. Since then, many synthetic GCs such as prednisolone and dexamethasone 
have been produced and they have widely been prescribed as forefront immunosuppressive 
drugs, in cases of many inflammatory, autoimmune (e.g. multiple sclerosis), allergic (e.g. 
asthma) and infectious (e.g. septic shock) disorders, graft rejections and malignancies of 
the immune system (e.g. lymphoblastic leukemia) [4-6]. 
Glucocorticoids: biosynthesis & secretion
GCs are synthesized from cholesterol in the mitochondria via a cascade of enzymatic 
reactions that include cytochrome P450c21 and P450c17, and result in the production of 
cortisol which is the main GC in primates and fish, and corticosterone, the main GC in 
rodents [7, 8]. Availability of active GCs is regulated by two isoenzymes -
hydroxysteroid dehydrogenase type 2 inactivates GCs by converting cortisol to cortisone 
(an 
   -hydroxysteroid dehydrogenase type 1 mainly regenerates the 
active forms of GCs [9]. 
Biosynthesis and secretion of adrenal GCs are controlled by upstream signaling 
cascades that constitute the Hypothalamic-Pituitary-Adrenal (HPA) neuroendocrine axis. 
Hypothalamic neurons release Corticotrophin-Releasing Factor (CRF) and Arginine 
vasopressin (AVP) that reach the pituitary and synergistically trigger the release of the 
Adrenocorticotropic Hormone (ACTH). The latter arrives, via the blood circulation, at the 
adrenals where upon binding to the melanocortin 2 receptor (MC2R), it orchestrates signal 
transduction (e.g. upregulation of steroidogenic gene transcription) that ultimately leads to 
the production and subsequent secretion of active GCs into the blood stream. Circulating 
GCs feed back to the level of the pituitary and the hypothalamus in order to suppress the 
production of ACTH and CRF, thereby negatively regulating their own secretion [10].   
Glucocorticoids: modulation of secretion & physiological effects  
During a 24 hour period, circulating levels of GC are not stable but fluctuate according to a 
circadian rhythm, imposed by the suprachiasmatic nucleus of the hypothalamus that 
interacts with CRF positive neurons and thereby directs the increase in circulating levels of 
GCs during active periods (daytime for diurnal animals) and lowers them significantly 
during resting periods (nighttime for diurnal animals) [11]. Importantly, circulating levels 
of GCs also peak upon stressful challenges. Stress can be defined as a physiological and 
complex reaction of the body towards (perceived) physical and emotional events that 
threaten or disrupt the homeostatic status of an organism. The hypothalamus is the brain 
region that perceives and integrates neuronal and humoral information concerning changes 
in body homeostasis and together with the sympathetic nervous system initiates a 




innervation mediates the rapid release of catecholamines from the adrenal medulla, 
whereas hypothalamic activation, via the HPA axis, leads to a relatively slow increase in 
the secretion of GCs from the adrenal cortex [16]. GCs are involved in an array of 
biological processes. Briefly, GCs catalyze carbohydrates, proteins and lipids and divert 
energy to the brain and the muscles, they promote liver gluconeogenesis, enhance 
cardiovascular tone, but suppress growth and reproduction as well as immune reactions
[12, 13]. Most likely, the physiological significance of this latter effect is to prevent the 
initial immune response from overshooting, which would be damaging to the organism 
[13]. For that purpose GCs suppress the production of cytokines, hinder leukocyte 
trafficking and interfere with the maturation and lifespan of a number of immune cells 
(e.g. they inhibit dendritic cell maturation, and induce apoptosis of T cells, eosinophils and 
basophils) [4, 17]. Among others, these effects have constituted the basis of the clinical use 
of GCs as very potent anti-inflammatory drugs. Nevertheless, the interplay between GCs 
and the immune system is very complex since GCs have also been demonstrated to 
enhance or prime certain inflammatory processes such as regulatory T cell and Th2 
differentiation, as well as antibody production [4, 17]. Furthermore, not all patients 
respond to GC treatment [18] and in addition to that, chronic exogenous administration of 
GCs can lead to deleterious side effects, such as skin atrophy, decreased wound healing, 
osteoporosis, muscle atrophy, glaucoma, psychosis, diabetes mellitus and hypertension 
[19]. Taken into consideration these issues, since the discovery of the effects of GCs on 
inflammation more than 70 years ago, intense scientific research is aiming to unravel the 
exact regulation and mechanisms of GC-mediated signal transduction towards specific 
cellular and molecular targets, the physiological role of GCs in various biological 
processes (at basal as well as elevated hormone levels) and their interaction with other 
molecular factors, especially within immune-related signaling pathways.
The Glucocorticoid Receptor: structure & activation
The physiological and pharmacological effects of GCs are mediated by the Glucocorticoid 
Receptor (GR), which is a member of the steroid receptor family of ligand-dependent 
factors, such as the estrogen and androgen receptor. In turn, these steroid receptors belong 
to the superfamily of nuclear receptors to which the Vitamin D Receptor and Thyroid 
Hormone Receptor belong as well. In mammals, the GR is expressed in nearly all 
nucleated cells of the body and is necessary for life, since its deletion hinders the 
maturation of the embryonic lungs [20] and the production of insulin-like growth factor-1
(IGF-1) from the liver that promoters postnatal growth [21].
The human GR gene was first cloned in 1985 and is encoded by a single gene, 
located in chromosome 5 [22]. It consists of 9 exons of which exon 1 is non-coding and 
represents the 5’ untranslated region [23]. The GR is a modular protein that is composed of 
distinct functional domains. Exon 2 encodes for the N-Terminal Domain (NTD) that is the 
immunogenic domain of the GR and harbors the activation fanction-1 (AF-1) region, 
which is required for optimal trasncriptional activity. Exon 2 and 3 encode for the DNA 
Binding Domain (DBD) that contains two zinc finger motifs through which the GR can 
bind to specific DNA sequences. The DBD also contains sequences corresponding to a 
weak dimerization interface as well as part of the first (ligand-independent) nuclear 
localization signal (NLS1). The rest of the NLS1 expands within the region adjacent to the 
DBD called the hinge region (encoded in exon 5) that confers structural flexibility in the 
receptor dimers and separates the DBD from the C-terminal part of the GR protein, the 
Ligand Binding Domain (LBD, encoded within exons 5-9). The latter is characterized by 
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 -	   -sheets that form a hydrophobic pocket for GC binding. The LBD 
contains the activation function-2 (AF-2) domain that upon hormone binding, interacts 
with transcriptional co-activators (which promote induction of transcription) or co-
repressors (which hinder transcription). Moreover, the LBD harbors a strong dimerization 
interface, an interaction interface with heat shock protein 90 (hsp90) and the second 
nuclear localization signal (NLS2). Upon ligand binding, the LBD undergoes a 
conformational change and hsp90 is released, thereby unmasking the NLS2 signal that 
subsequently allows translocation of the activated GR to the nucleus [3, 24, 25]. 
In the absence of hormone, the GR resides predominantly in the cytoplasm where it 
is embedded in a multiprotein complex containing heat shock proteins (e.g. hsp90, 70, 50) 
and immunophilins (e.g. FKBP51). Upon hormone binding, a conformational change 
occurs, the ligand-bound GR is released from its protein complex, phosphorylated at Ser 
211 and is actively imported into the nucleus where it acts as a transcription factor [3, 24,
26].  
The Glucocorticoid Receptor: modes of transcriptional activity 
Activated GR modulates that transcription rate via DNA binding-dependent and -
independent mechanisms that confer up- or downregulation of gene expression. For its 
DNA binding-dependent transcriptional activity, the GR forms a dimer and recognizes 
glucocorticoid response elements (GREs) within promoters of target genes. GREs are 
palindromic motifs, similar to the 15bp consensus sequence 5’-AGAACAnnnTGTTCT-
3’[26]. Genes can have one or many GREs in order to be used for GR-mediated regulation 
of transcription. GREs can also be combined with other response elements specific for 
different transcription factors (e.g. C/EBP and FoxA) that synergistically with the GR 
promote gene expression (e.g. in the case of the gluconeogenic phosphoenolpyruvate 
carboxykinase (PEPCK) gene) [26]. This mode of upregulating transcription is termed as 
transactivation and can be observed, for instance, in the case of many metabolic enzymes 
(e.g. the tyrosine aminotransferase and tyrosine oxygenase gene involved in amino acid 
degradation, and the 6-phosphofructo-2-kinase gene involved in gluconeogenesis) as well 
as anti-inflammatory mediators (e.g. glucocorticoid-induced leucine zipper (GILZ),
lipocortin, Map kinase phosphatase-1 (MKP-1), and nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, alpha (!"#-)) [26, 27]. Moreover, so-
called negative GREs (nGREs) are present in genes of which the transcription rate is 
downregulated by GR [28]. For instance, the CRF and pro-opiomelanocortin (POMC)
genes (the latter encodes an ACTH precursor protein) contain nGREs via which GC-
mediated negative feedback on the HPA occurs, as well as the osteocalcin gene, whose 
product is important for bone formation and mediates GC-induced osteoporosis, a well-
known side effects of GC treatment [26]. Once bound to GREs, the GR dimer via its AF-1
and AF-2 surfaces acts as a scaffold for coactivators (e.g. the SRC-1, -2, and -3 proteins)
that that possess enzymatic activity in order to modify (e.g. acetylate) the core histones, 
thereby relaxing the chromatin structure for induction of gene transcription [2, 3, 24, 26], 
or recruit basal elements of the transcriptional machinery and in this way bridge the DNA-
bound receptor to the RNA-polymerase II complex for initiation of transcription. GR-
bound in nGREs may favor recruitment of chromatin remodeling factors with enzymatic 
activities (e.g. deacetylation) that would compact chromatin, thus hindering transcription. 
Alternatively, nGREs can overlap with other response elements, thus preventing binding of 




DNA binding-independent mechanisms of ligand-bound GR involve physical 
interaction of the activated receptor (as a monomer) with other transcription factors, 
thereby enabling either (synergistic) induction of genes (e.g. in the case the induction of 
IGF-1 by STAT5 [23]) or suppression of genes (e.g. in the case of NF-"#$%-1 activity 
on the promoter of a large number of cytokine genes [2, 3, 10, 23, 26, 29]). The latter 
mode of action is termed transrepression and comprises one of the classical mechanisms 
by which GCs exert their anti-inflammatory effects [2, 3, 10, 24, 26, 29, 30].
Receptor variants deriving from a single Glucocorticoid Receptor gene
GCs are one of the most pervasive hormones in mammals and the GR is ubiquitously 
expressed. The receptor orchestrates the expression of a plethora of genes involved in 
various physiological processes such as intermediate metabolism, stress response, 
inflammation, growth and brain function [31]. These diverse effects in different tissues 
that ensure homeostasis can be exerted by the specific availability of several GR subtypes 
with different molecular profiles [32].
Its exon 1 (that is non-coding and represents that 5’ untranslated region) harbors 
different transcriptional start sites, which are associated with unique promoters (that do not 
contain classical TATA or CCAAT boxes) and they are thought to account for differential 
gene expression regulation of the GR gene throughout the body [23]. Exon 2 encodes for 
alternative translational start sites that give rise to 8 GR isoforms with progressively 
shorter N-termini, from which the classical GR protein represents the longest variant. 
These isoforms differ in their cellular distribution and transcriptional properties [25].
Moreover, several subtypes derive from alternative splicing of the human GR pre-
mRNA. The canonical receptor isoform (&) is translated from an mRNA that contains 
9 exons and is the predominant splice variant expressed in most cells. A much less 
' & 
() 
 & *) + + 

+    		

splice site within exon 9 [22, 33],&& 
	
*	
and 727, thus sharing the same NTD and DBD, and only differ in the C-terminal part of 






,  & -isoform contains 742 amino 
acids, and has a shorter LBD with a unique C-terminal 15 amino acid sequence, which 
renders it unable to bind GCs [22, 33, 34].
Using in vitro reporter assays, hGR was shown to have a pronounced dominant-

+ 	




 [35-37], and &-mediated 




Further cell culture-based research supports an 
(   &  
 &-
induced transactivation and transrepression of endogenous genes (MKP-1, myocilin, 
fibronectin, tumor necrosis factor  234) and interleukin 6 (IL6) [38-40], as well as on 
&-mediated regulation of cell death, proliferation and phagocytosis [41-43]. These 
findings are in line with clinical data demonstrating a positive correlation between high 
expression levels of the hGR -isoform and GC resistance of patients suffering from 
immune-related disorders, like asthma [40, 44-48], ulcerative colitis [49-51], leukemia 
[52-54] and rheumatoid arthritis [55, 56]. Interestingly, hGR expression has been shown 
to be increased in several types of human cells (e.g. HeLa, neutrophils, PBMC, ASM cells) 
upon stimulation w
+	(
52,,34, IL1, IL2, IL4, IL7, IL8, IL17A and F, 
IL18, interferons) [41, 44, 57-60]. Furthermore, a single nucleotide polymorphism within 






polymorphism has been associated with increased insensitivity for GC-mediated 
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activity. Overexpression of this receptor isoform has been demonstrated to attenuate 
induction of luciferase reporter constructs by NF-"#  $%-1[62], as well as GATA3-












(&activity [64, 65]. 
6+) 
 & -isoform’s physiological relevance has often been questioned 




properties could not be demonstrated in in vitro reporter assays [62, 63, 66-71]. Second, 
despite the fact that hGR is expressed in almost all human tissues, its expression levels 
	
(	*
&[35, 36, 41, 72-74]. This raises doubts about its 
in vitro dominant negative effect, since in most studies this requires transfection of a 10-
*'	&'+	
	*







'&-isoform was only found in 
humans, and that rodents contained a mutation in the splice site required for GR
expression [75]. Recently howe+)  -isoform was discovered in mice [76] as well as 
zebrafish [77] and its molecular characterization showed that it has a defective LBD 




properties in reporter assays [76, 77]. This has opened up a new chapter i&	
providing new tools and, most importantly, in vivo systems to investigate more thoroughly 
the exact role of this receptor and its mechanisms of action. 
$
 * &) three more alternative splice variants have been identified
(reviewed by Oakley et al. [25]). The hGR 7-isoform has an insertion of an arginine 
residue between the two zinc fingers of the DBD and is a result of the utilization of an 
alternative splice donor site in the intron separating exons 3 and 4. This isoform can bind 




presence has been associated with various cancer tissues. hGR-A is derived from 
alternative splicing that links the end of exon 4 to the beginning of exon 8, and thus misses 
the N-terminal part of its LBD (encoded by exons 5-7). hGR-P is derived from a failure to 
splice at the exon7/8 boundary, which causes a lack of exons 8 and 9 that encode the C-
terminal half of the LBD. Both hGR-A and hGR-P were discovered in GC-resistant 
multiple myeloma cells, and the latter receptor appears to be the predominant receptor 






	-specific manner [25].  
Finally, post-translational modifications focus of phosphorylation that modulates 
the transcriptional activity of the receptor, its half life and its cellular trafficking, whereas 
ubiquitination, sumoylation and acetylation have also been shown to play a role in 
regulating its degradation by the proteasome and its transcriptional properties [25].  
The zebrafish as a model organism for biological research 
Although traditionally used as a model organism for vertebrate development, over the last 
decade, the zebrafish has emerged in biomedical research as an important in vivo model 
system for studies on a variety of human diseases [78-80]. Especially the high level of 
similarity of its immune response to that of mammals [81] provides an excellent research 
platform for modeling various molecular and cellular elements of inflammation such as 




sites [82, 83]. Zebrafish are small, easily maintained and breed well under laboratory 
conditions. Each female can produce hundreds of eggs per day that are fertilized 
externally. Upon fertilization, the embryos develop rapidly, thus providing an excellent 
model system for the study of embryonic development. Precursors to all major organ 
systems have been formed within 36 hours after fertilization, and embryos progress to the 
larval stage within less than 3 days [84]. Their ex utero development and optical 
transparency allow for microscopic imaging at the cellular and even subcellular level, 
especially when performed in combination with fluorescent labeling of specific cells or 
proteins [85-87].
The zebrafish offers a valuable genetic vertebrate model system for both forward-
and reverse-genetic studies. The zebrafish has been used in forward-genetic studies for the 
unbiased identification of pathways responsible for embryonic development, heart 
development, axon guidance, visual behaviour, axon myelination and many more using 
phenotype to genotype mutant screens [88-91]. Due to their small size and large number of 
offspring mutant screens are relatively fast and inexpensive [88, 89]. In these screens, 
adult fish are subjected to chemical mutagenesis and their offspring is studied for 
abnormalities. This approach provides an unbiased method for assigning functions to novel 
or already known genes.
Reverse genetics in zebrafish is facilitated by the completion of the entire zebrafish 
genomic sequence and by the possibilities of genetic manipulation via microinjections of 
DNA, mRNA and morpholinos at 1-2 cell stage embryos [92, 93]. The latter are 
chemically modified antisense oligomers that provide transient knockdown of specific 
genes [94]. Morpholinos affect protein synthesis by blocking the translation start site of an 
mRNA molecule, or alter the mRNA splicing pattern by blocking specific splice acceptor 
or donor sites. Furthermore, an increasing number of transgenic, mutant and knockout 
zebrafish lines are available (e.g. knockout lines generated by TILLING [95]) as well as 
several zebrafish cell lines derived from embryos and adult tissues, that can be used as a 
complementary tool allowing more refined biochemical characterizations [96, 97].
The zebrafish as a model organism for glucocorticoid signaling
In fish, cortisol secretion is regulated by a stress axis similar to those in mammals. Whole 
mount RNA in situ hybridization studies using well-characterized markers for different 
hypothalamic and pituitary cell types has shown that these cell types are present in 
zebrafish larvae [98-100]. However, there are anatomical differences between fish and 
mammals. The adrenal gland in mammals is homologous to the interrenal gland in fish, a 
structure embedded in the anterior part of the kidney in fish. The hypothalamus and 
pituitary in larval stages are shaped along the anterior/posterior axis in contrast to the 
equivalent structures in mammals which are shaped along the dorsal/ventral axis [99].
Moreover, the zebrafish pituitary lacks a stalk-like structure and as a result it is located
closer to the hypothalamus compared to the mammalian pituitary [99].
The GR has been conserved well through evolution. It is found in jawed 
vertebrates, and not in jawless vertebrates, like the lamprey, dating back its origin to ~ 450 
million years ago [101, 102]. After the lineage leading to tetrapods (encompassing 
amphibians, reptiles, birds and mammals) branched off from the teleost (bony fish) lineage
a gene duplication occurred in the teleost lineage [103]. Due to this genome duplication, 
most teleost fish genomes contain two genes encoding for GR [104]. The presence of two 
GRs has been demonstrated in rainbow trout [105], Burton’s mouthbrooder [106], green 
spotted puffer [104], fugu [104], common carp [107], and sea bass [108, 109], and the 
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resulting isoforms are called GR1 and GR2. Both GRs are functional receptors, but EC50s 
in in vitro transactivation assays differ between GR1 and GR2 in several species. It is 
therefore suggested that GR1 and GR2 are active at different cortisol concentrations in 
vivo [105, 106, 110]. 
Surprisingly, to date only one isoform has been identified in zebrafish [77, 104,
111]. Phylogenetic analysis of the teleost GRs shows that the zebrafish GR clusters in the 
GR2 clade, which suggests that the GR2 gene has been conserved and the GR1 gene has 
been lost during the evolution of the zebrafish [77, 104]. Syntenic analysis of the genomic 
region surrounding the GR1 gene in several fish species confirms this hypothesis [77]. The
loss of the GR1 gene appears to have occurred less than 50 million years ago, since the 
common carp, a close relative of the zebrafish, is known to have two GR genes [107, 112].
The zebrafish GR gene (zGR) is organized similarly to the human GR gene (Fig.1). It 
consists of 9 exons of which exon 2 contains the translational start site and exon 9 the 
translation stop site and the 3’UTR. At the protein level, a similarly high level of 
homology is observed [77, 104]. The DBD of the zGR shows 98.4% similarity with the 
DBD of the human GR, and this percentage is 86.5% for the LBD. The NTD is less well 
conserved and displays 39.6% of similarity between human and zebrafish [77]. 
The zebrafish GR -isoform
Interestingly, the zGR gene encodes 
	+
)
&- -isoform (Fig. 1).
Like their human equivalents, the zGR - and -isoforms share the same NTD and DBD 
and only differ at the C-terminus of their LBD. However, the gene organization and 
splicing events leading to the expression of GR are different between humans and 
zebrafish. Whereas in humans the zGR-specific sequence is found in exon 9, in the 





donor site leads to an extended version of exon 8 that introduces a stop codon within that 
') 
   *&3$ 	 & [77], ) 
 *   -
isoforms are generated through different splicing mechanisms and there is low homology 

 
 -specific sequences, but they share the same point of divergence at the 
protein level [77, 113]. An alternative splicing event in exon 8 similar to that leading to the 
expression of a GR -isoform in zebrafish was recently discovered in mice [76].  
Additionally) 
 





-negative inhibitor of 






All these data point to convergent evolution of hGR and zGR, which most likely 
emerged due to a common biological need for regulation of specific signaling pathways 
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Figure 1: The zebrafish GR. A. The human and zebrafish &
,The percentage amino 
acid  similarity is indicated for individual receptor domains and the full length receptor. B. The 
human and zebrafish GR genes. Both genes contain 9 exons, of which exon 1 is non-coding. A
remarkable difference is the location of the sequence encoding the -isoform-specific amino acids. 
In the human gene, this sequence is located in exon 9, whereas in the zebrafish gene it is found in 
exon 8. In zebrafish, the use of the most 5’ splice donor site in this exon results in a shorter version 
of exon 8 and an open reading frame that extends into exon 9, resulting in mRNA encoding zGR
(GenBank Acc No. EF436284). The use of the most 3’ site results in an extended version of exon 
8, introducing a stop codon in exon 8, which results in zGR mRNA (Acc No. EF436285). The 
resulting GR protein isoforms are identical between amino acids 1 and 696. An additional 41 







*&-specific C-terminus. DBD: DNA binding domain. LBD: ligand 
binding domain
Glucocorticoid signaling research using the zebrafish
The zebrafish could be a valuable tool for at least two types of GC research. First, the 
zebrafish can be used to advance our knowledge on the molecular mechanisms underlying 
the effects of GR activation in vivo. Using techniques for transient or stable genetic 
manipulation in combination with imaging-based phenotypic readouts, the zebrafish can be 
used for analysis of how specific molecular mechanisms alter the phenotype of a living 
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vertebrate organism. Most of these phenotype-based assays are based on the imaging of 
fluorescent cells in zebrafish embryos that could be used on a relatively large number of 
individuals. Second, its potential could be used in studies towards the discovery of novel 
drugs and drug targets [114, 115]. Because of its small size and suitability for imaging 
studies, the zebrafish could be an ideal tool for the screening of novel glucocorticoid 
drugs. These screening assays could be implemented as an extra step between high-
throughput drug screening assays (often performed in cell cultures) and subsequent studies 
in mammalian animal models like rodents. This way, compounds which appear to be 
ineffective in in vivo studies are filtered out at an early stage, limiting the number of 
compounds to be tested in mammalian models. In addition, using forward-genetic screens 
using glucocorticoid responsiveness as readout, novel drug targets may be discovered that 




Several mutant zebrafish lines possibly interesting for GC research are available. A mutant 
zebrafish line is available that carries a mutation in the retinal homeobox gene 3 (rx3), 
resulting in a loss of corticotrope cells in the pituitary and severely reduced cortisol levels 
[116, 117]. In addition, other cortisol-deficient mutants lack the entire pituitary, like the 
fibroblast growth factor 3 mutant (lia/fgf3 [118]) and the achaete scute-complex like 1a 
mutant (pia/ascl1a [119]). Another mutant, eyes absent 1 (aal/eya1 [120]), only contains 
the lactotrope cells of the pituitary. 
In addition, a few relevant morpholino studies have been performed. Transient 
knockdown of steroid biosynthesis using a morpholino reducing the cyp11a1 gene 
expression (the enzyme which converts cholesterol into pregnenolone, the first step in the 
steroid biosynthesis pathway) results in severe developmental defects, but which class of 
steroids is responsible for this effect is yet unclear [121]. In another study a morpholino 
approach was used to knock down GR function by blocking the splice acceptor site at the 
5’end of exon 6, resulting in a GR transcript that lacks this exon [114]. The altered splicing 
results in an mRNA that encodes a GR protein lacking its LBD. Injection of this 
morpholino did not result in any obvious early developmental defects, suggesting that GR 
is not essential for early embryonic development [114]. This does not mean that alterations 
in GR function do not affect embryonic development, since GC treatment during the first 
days of development has been reported to result in craniofacial abnormalities, altered 
somitogenesis, blood pooling and pericardial and yolk sac edema [122, 123]. 
<'+&&*&3$	
*(/%&[77, 111,
114, 117] and the expression pattern has been studied by in situ hybridization [77]. For
detection at the protein level, western blotting [117] as well as immunohistochemistry on 1 
day old embryos [124] have been performed using an anti-human GR antibody (p-20, 
available from Santa Cruz), which is directed against the receptor C-terminus, and is 
therefore specific for 
 & -isoform. Moreover, in zebrafish embryos treated with 
synthetic GCs such as dexamethasone, qPCR analysis revealed the transcriptional 
upregulation of fkbp5, gilz, nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha a (nfkbiaa) and pepck, and the suppression of il8, il1b and tnfa, all of 
which are well-known GR target genes in mammals [114, 124]. Hence, alterations in the 
expression of these GR target genes can be used as readouts of GR transactivation and 





Using zebrafish embryos and larvae, the immunomodulatory properties of GCs could 
easily be tested and characterized in vivo. It should be noted that zebrafish embryos and 
early-stage larvae only contain an innate immune system, and that cells representing the 
adaptive immune system (e.g. lymphocytes) start to mature at the second week of zebrafish 
development [125-127]. First, the actions of GR signaling in the cellular activity (e.g. 
trafficking, apoptosis) of zebrafish immune cells upon inflammation can be explored, 
based on fluorescently labeled cells. A transgenic fish line can be utilized containing the 
green fluorescent protein (GFP) gene driven by the myeloperoxidase (mpo) promoter, 
expressing GFP in the neutrophil granulocytes [128, 129]. These cells migrate to the site of 
injury after a wound has been made, and this experimental paradigm is considered as a 
model for acute inflammation [128]. Treatment of embryos with the synthetic GC 
beclomethasone results in a significant decrease in the number of neutrophils migrating to 
the trauma site upon amputation of a part of the tail [114]. A transgenic line expressing 
yellow fluorescent protein (YFP) in a subset of neutrophils [130], and a line expressing 
GFP in a subset of macrophages (with the GFP expression driven by the lysozyme C 
promoter [131]), have been used in similar assays of immune cell migration. In addition, 
several other transgenic lines are available in which a subpopulation of immune cells 
express GFP [132, 133]. Moreover, a transgenic zebrafish line that models chronic 
inflammation has been generated (caused by a mutation of the hepatocyte hai1 gene), that 
shows accumulation of (GFP-labeled) neutrophils in the fin [134].
Second, the presence of T-cells in the thymus can be monitored. A transgenic 
zebrafish line can be used that expresses GFP under control of the T-cell specific tyrosine 
kinase promoter, resulting in GFP-labeled T cells. Treatment of embryos from this line 
with the GR agonist dexamethasone results in the ablation of GFP-labeled T-cells in the 
thymus of these embryos [135]. Another line in which GFP expression is controlled by the 
rag2 promoter (resulting in GFP labeled immature T and B cells) showed similar results 
[135].
Third, several zebrafish infection models exist in which the status of the infection 
can be monitored. An increase in the proliferation of the infectious agent could be used as 
a measure for the immunosuppressive activity of a GR agonist. Infecting zebrafish 
embryos with fluorescently labeled bacteria enables the analysis of the infection in real
time and in situ. This approach has been successfully used for Mycobacterium marinum
and Salmonella typhimurium infections [136, 137].
In addition to their use in screening assays for the anti-inflammatory activity of 
GCs, zebrafish embryos can also be used for screening of other effects of GC treatment, 
like decreased bone formation which is a common side effect of GC treatment. A zebrafish 
model system for GC-induced osteoporosis has been developed, based on the visualization 
of skeletal structures of zebrafish larvae using calcium-binding dyes like calcein or alizarin 
red [138, 139]. As a proof of principle, treatment of 5-day-old zebrafish larvae with 
prednisolone, a GC that is widely used clinically, significantly reduced bone formation in 
this assay [140]. Using these assays at this stage of development restricts the screening to 
the osteoblast activity, since the first osteoclasts appear in 20 day old individuals [141].
Another common side effect of GC treatment is a decrease in circulating cortisol 
levels, and this effect can be studied in zebrafish as well. Total cortisol levels can be 
measured in homogenates from pools of zebrafish embryos of any age using an immuno-
assay [111, 117]. Increased cortisol levels in response to a stressor can be detected from 97 
19
 
hours post fertilization [111], and a circadian rhythm in cortisol level has been observed at 
6 days post fertilization [117]. This indicates that the hypothalamus pituitary interrenal 
(HPI) axis is functional in zebrafish larvae, and it can be expected that GC treatment 
results in a decrease in circulating cortisol levels.
Scope of the present thesis
GR signaling plays an essential role in the survival and well-being of organisms. GCs are 
also widely used clinically in order to combat inflammatory medical conditions. GR 
signaling is versatile, with diverse effects and complex interactions with other molecular 
components. Nevertheless, its complete biological significance and exact mechanisms of 
regulation and action have not fully been elucidated. In the present thesis we aimed at 
studying the GR pathway by means of stimulation with synthetic GCs and genetic 
manipulation. Since the GR is a transcription factor, our main readout for GR function in 
most of our experimental settings was transcriptome analysis. By gathering whole 
transcriptome information, we aimed at unraveling the molecular pathways affected by GR 
signaling in different physiological conditions, thus exploring its functional role. As a 
model organism we employed the zebrafish, since it allows fine genetic, molecular and 
cellular experimental approaches and its GR pathway closely resembles that of humans. 
Our aim was also to further characterize the function of this versatile signaling cascade in 
zebrafish, in order to establish this animal model as a valid system for detailed as well as 
high throughput research on GR, enabling us to test hypotheses and complement results 
obtained from other well-established experimental animal models such as rodents. 
In chapter 2)  + ' 






inflammatory response to a wound injury. For that reason, a tail fin amputation assay was 
employed in 3 day old zebrafish larvae which were subsequently treated with the synthetic 
GC beclomethasone. Amputation elicited a migratory behavior for both macrophages and 
neutrophils as well as induction of several immune-related signaling routes. Using cell 
imaging as well as whole transriptome analysis, we have studied the GC effect on the 
cellular trafficking of leukocytes as well as on the transcriptional rate of genes involved in 
molecular networks altered due to amputation.   
In chapter 3, we have investigated the specificity and function of bot & -  -
isoforms. Zebrafish embryos were injected with two splice-blocking antisense oligos (one 

5	5
&- -isoforms, and another targeting the alternative 
splicing of the zGR pre-*&3$  +  






the synthetic GC 
dexamethasone and transcriptome analysis was performed using microarray technology. 





















In chapter 4, we have embarked on a series of experimental settings in order to elucidate 
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answering two questions. First, wh
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&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at 1-2 cell-stage zebrafish embryos. Furthermore, we oberexpressed the zGR -isoform 

() ( 
   &-overexpressing cell line and a GFP-&
overexpressing transgenic fish line. Results were assessed by means of luciferase assays 
and transcriptome analysis.
In chapter 5, results from all 3 experimental chapters are evaluated collectively in order to 
draw solid conclusions about the role and function of both zGR splice variants. In 
particular, the functional role of zGR in different physiological conditions and the 
	 		  
 & -isoform are discussed. In addition, the zebrafish 
embryonic model as a system for further GR signaling research is evaluated. Future 
experimental approaches, employing the zebrafish model, are proposed that can be 
undertaken in order to further elucidate the versatile and complex nature of the GR 
signaling. Finally, summaries of our work from our 3 previous experimental chapters, 
written both in English and Dutch, are also included in this chapter.
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Glucocorticoids are steroid hormones that are secreted by the adrenal gland upon stress. 
Their effects are mediated by the glucocorticoid receptor (GR) which acts as a 
transcription factor, regulating a wide plethora of genes. Since anti-inflammatory activity 
of glucocorticoids has been well established, they are widely used clinically to treat a 
variety of inflammatory and immune-related diseases. However, the exact specificity, 
mechanisms and level of regulation of different inflammatory pathways by GR signaling 
have not fully been elucidated. In the present study, a tail fin amputation assay was 
employed in 3-day-old zebrafish larvae in order to study the immunomodulatory effects of 
the synthetic glucocorticoid beclomethasone, using cell imaging as well as whole 
transriptome analysis. Our results show that amputation induced migration of both 
neutrophils and macrophages towards the wound site, and that beclomethasone treatment 
attenuated the migratory behavior of only neutrophils. In addition, the expression of many 
pro-inflammatory genes was induced upon amputation and this induction was suppressed 
by beclomethasone for virtually all induced genes. Apparently, glucocorticoid treatment 
has a very general dampening effect on the induction of gene expression upon amputation, 
without any specificity for particular pathways. These results show that the zebrafish larva 
model of tail fin amputation and beclomethasone treatment recapitulates the well known 
anti-inflammatory glucocorticoid effects, thus providing a reliable model system to further 
elucidate the molecular mechanisms of glucocorticoid signaling. 
Introduction 
Glucocorticoids (GCs) are potent anti-inflammatory agents that have been widely used 
clinically over the last 50 years for the treatment of many inflammatory and autoimmune 
diseases, graft rejection and malignancies of the immune system [1, 2]. The effects of GCs 
are mediated by the glucocorticoid receptor (GR), which is a nuclear receptor that is 
expressed almost ubiquitously in the human body and regulates a wide range of biological 
processes such as our metabolism, growth, reproduction, vascular tone, bone formation, 
immune response and brain function [3-8]. In its inactive state, the GR resides within the 
cytoplasm in a multiprotein complex containing chaperones and immunophilins [9]. Upon 
GC binding, it is released from this cytoplasmic complex and translocates to the nucleus, 
where it orchestrates gene expression via DNA-binding-dependent and -independent 
mechanisms. DNA-binding-dependent mechanisms involve GR occupancy of 
glucocorticoid response elements (GREs) and recruitment of transcriptional coregulators, 
resulting in a modulation of the transcription rate of target genes. Independent of DNA-
binding, the GR can physically interact with other transcription factors via which it can 
either enhance the activity of these factors (e.g. in the case of STAT-5 activity on the IGF-
1 promoter [6] or repress their activity (e.g. in the case of NF-κB or AP-1 activity on the 
promoter of a large number of cytokine genes) [3, 4, 6, 10-12]. The latter mode of action is 
termed transrepression and comprises one of the main mechanisms by which GCs exert 
their anti-inflammatory effects [3, 4, 9-13].
Many in vitro and in vivo studies have been performed to elucidate the cellular and 
molecular mechanisms underlying the effects of GR signaling on the immune system (for a 
review see Franchimont et al. [14]). From these studies it appeared that GCs suppress 




cytokines (e.g. IL1β, IL6, TNFα), chemokines (e.g. CCL1, CXCL8), enzymes (e.g. iNOS, 
COX-2) and adhesion molecules (e.g. ICAM-1), while the expression of several anti-
inflammatory mediators is upregulated (e.g. DUSP1, IκB, IL10, TGFβ, ANXA1, GILZ) 
[2, 14, 15]. Furthermore, the synthesis of pro-inflammatory agents like prostaglandins, 
leukotrienes, proteolytic enzymes, free oxygen radicals, and nitric oxide is also inhibited 
by GCs [14]. Nevertheless, the exact specificity, mechanisms and level of regulation of 
different inflammatory pathways by the GR signaling have not fully been elucidated. For 
example, several studies have even revealed immunoenhancing effects of GCs, like the 
induction of Toll-like Receptor (TLR)2 and TLR4, the secretion of MIF (Macrophage 
Inhibitory Factor) and the upregulation of IL7Ra which is involved in T cell development 
[14, 16].  
The aim of the present study is to establish a robust in vivo model to investigate in 
detail the molecular mechanism of the anti-inflammatory action of GCs. Profound 
understanding of the complex interplay of GR with the different components of the 
immune response may ultimately lead to improved GC treatment regimens, which would 
be of great importance, since the clinical use of GCs is currently limited by two problems: 
the deleterious side effects such as skin atrophy, decreased wound healing, osteoporosis, 
muscle atrophy, glaucoma, psychosis, diabetes mellitus and hypertension [17], and the 
minority of patients that shows complete or partial resistance to GC treatment [18].  
Over the last decade, the zebrafish has emerged in biomedical research as an 
important model system for a variety of human diseases [19-21]. It is easily handled and 
maintained and produces big clutches of eggs, which are fertilized externally and develop 
rapidly [22]. Moreover, its genome has been sequenced and embryos can easily be 
subjected to genetic manipulations [22, 23]. Additionally, the zebrafish immune system 
remarkably resembles that of mammals [24], thus providing an excellent research platform 
for modeling various molecular and cellular elements of inflammation such as host-
pathogen interactions during infectious diseases and immune cell migration to wound sites 
[25, 26]. In the present study, zebrafish larvae are used at three days post fertilization. At 
this stage, two types of leukocytes are present which constitute the innate immune system, 
macrophages and neutrophils [27-31]. Cells representing the adaptive immune system, like 
lymphocytes, start to mature at the second week of zebrafish development [32-34].  
Furthermore, the zebrafish is considered as a potent model organism for GC 
research [35-39]. Zebrafish have a single GR gene which encodes a GR protein that upon 
activation mediates gene transcription in a similar way as its human equivalent [35, 38, 40, 
41]. This zebrafish GR gene also encodes a splice variant, zGRβ, which is the equivalent 
of the human GR β-isoform [39] that may play a role in resistance to glucocorticoid 
treatment in humans. As in all teleost fish, cortisol is the main endogenous GC in 
zebrafish, like in humans, and its secretion is regulated by the hypothalamus pituitary 
interrenal (HPI) axis, which is the equivalent to the mammalian hypothalamus pituitary 
adrenal (HPA) axis [36, 37, 42].  
Local inflammation can be modeled in zebrafish by amputation of the tail fin of 
zebrafish larvae [43]. Amputation induces the expression of many pro-inflammatory 
mediators at the wound site and migration of the two types of leukocytes present at the 
larval stage, neutrophils and macrophages, towards the site of amputation [41, 43-45]. 
Interestingly, it has been demonstrated that this migration is inhibited by glucocorticoid 
treatment and therefore this model system enables studying of the anti-inflammatory action 
of glucocorticoids in an in vivo situation [41, 45]. 
In the present study we have used the zebrafish tail fin amputation model to study 
glucocorticoid effects on leukocyte migration and associated changes in gene expression at 
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the whole transcriptome level. Our results demonstrate that glucocorticoid treatment 
specifically inhibits the migration of neutrophils and not of macrophages. In addition, we 
show that tail fin amputation affects the expression of a wide variety of genes, among 
which many inflammation-related ones, and that glucocorticoid treatment attenuates the 
vast majority of these changes. Thus, glucocorticoids appear to dampen the inflammatory 
response in this model system, without any apparent specificity for particular signaling 
pathways.  
Materials & Methods 
Zebrafish strains, husbandry & egg collection 
Zebrafish were maintained and handled according to the guidelines from the Zebrafish
Model Organism Database (ZFIN, http://zfin.org). Fertilization was performed by natural 
spawning at the beginning of the light period and eggs were raised at 28.5 C in egg water 
(60μg/ml Instant Ocean sea salts supplemented with 0.0025% methylene blue (GUUR)). 
All experimental procedures were conducted in compliance with the directives of the local 
animal welfare committee of Leiden University.
Tail amputation & GC treatment 
Three-day-old embryos were anesthetized in egg water containing 0.02% buffered 
aminobenzoic acid ethyl ester (tricaine, Sigma) and aligned in Petri dishes coated with 2% 
agarose for subsequent partial amputation of the tail fin as shown in Fig. 1. Amputation 
was performed using a 1mm sapphire blade (World Precision Instruments) using a Leica 
M165C stereo-microscope and a micromanipulator. Amputated and non-amputated 
embryos were pretreated for 2h with either 25μM beclomethasone (Sigma) or vehicle 
(0.05% DMSO) prior to amputation and again for a specified period of time after 
amputation (see Results section). For migration studies samples were fixed in 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) and stored at 4 C, whereas 
for gene expression analysis samples were collected in TRIzol® reagent (Invitrogen).  
Myeloperoxidase staining and whole mount immunohistochemistry for visualization of 
macrophages and neutrophils 
Embryos were fixed in 4% PFA overnight at 4 C and following washes with PBS 
containing 0.1% Tween 20 (PBST), the Myeloperoxidase (mpx) activity was detected 
using the Leukocyte Peroxidase kit (Sigma) according to the manufacturer’s instructions. 
Mpx staining was always performed prior to L-plastin immunohistochemistry. For this 
purpose, embryos were washed in PBST, gradually dehydrated with methanol in PBS and 
stored in 100% methanol overnight at 4 C. The next day embryos were rehydrated with 
graded series of methanol in PBS containing 0.8% Triton X-100 (PBS-TX) and incubated 
with 10μg/ml Proteinase K (Roche) for 10min at 37 C. Embryos were then incubated in 
PBS-TX blocking buffer (containing 1% BSA) for 2h at RT and subsequently in blocking 
buffer containing a rabbit anti-L-plastin polyclonal antibody (provided by Dr. A. 
Huttenlocher [46], 1:500 dilution) overnight at 4 C. Following washes with PBS-TX,
embryos were incubated again in blocking buffer for 1h at RT prior to incubation with goat 
anti-rabbit Alexa Fluor® 568 dye–labeled secondary antibody (Invitrogen) for 2h at RT 




Imaging of the embryos was performed using a Leica MZ16FA fluorescence 
stereo-microscope supported by the LAS version 3.7 software. Macrophages were detected 
based on the red fluorescent labeling by the immunehistochemistry and neutrophils were 
detected based on their dark brown appearance as a result of the Mpx assay (although they 
are stained by both methods, the L-plastin immunolabeling is hard to detect in these cells 
due to the dark staining of the Mpx assay). To determine the number of cells that had 
migrated to the wounded area, the cells posterior to the caudal vein were counted (marked 
by the dashed red box in Fig. 1B). Data shown are means (±s.e.m.) of three individual 
experiments. In each experiment, treatment groups consisted of at least 20 larvae. 
 
RNA isolation & cDNA synthesis 
Total RNA was extracted using TRIzol® reagent (Invitrogen) according to the 
manufacturer’s instructions (Invitrogen). RNA was dissolved in water and denatured for 
5min at 60 C. Samples were treated with DNAse using the DNA-free™ kit (Ambion). For 
microarray analysis, RNA was further purified using the RNeasy MinEluteTM Cleanup kit 
from Qiagen and its integrity was checked with a lab-on-chip analysis using the 2100 
Bioanalyzer (Agilent Technologies). For subsequent cDNA synthesis, 1μg of total RNA 
was added as a template for reverse transcription using the iSCRIPTTM cDNA Synthesis 
Kit (Biorad). 
 
Quantitative Polymerase Chain Reaction (qPCR)  
QPCR analysis was performed using the MyiQ Single-Color Real-Time PCR Detection 
System (Biorad). PCR reactions were performed in a total volume of 25μl containing 6.5μl 
diluted cDNA, 1μl forward and reverse primer (10μM) and 12.5μl of 2x iQ™ SYBR® 
Green Supermix (Biorad). Cycling conditions were 95 C for 3min, followed by 40 cycles 
of 15sec at 95 C, 30sec at 60 C and 30sec at 72 C. Ct values (cycle number at which a 
threshold value of the fluorescence intensity was reached) were determined for each 
sample. A dissociation protocol was added, determining dissociation of the PCR products 
from 65 C to 95 C, allowing discrimination of specific products. In all qPCR experiments, 
a water-control was included. Data shown are means (±s.e.m.) of three individual 
experiments. In each experiment, cDNA samples were assayed in duplicate. Sequences of 
all primers used for qPCR analysis are included in Suppl. Table 5. 
 
Microarray design 
A 4x180k microarray chip platform (customized by Agilent Technologies, (Design 
ID:028233)) was used in this study. This array consists of all probes already present in an 
earlier 45.219 custom-made array [47], and another 126.632 newly designed zebrafish 
probes had been added as described in [48]. A total of 16 samples (4 experimental groups 
from 4 replicate experiments) were processed for transcriptome analysis and were 
hybridized against a common reference.  
 
Microarray amplification & labeling 
Amplification and labeling of RNA was performed at the MicroArray Department (MAD) 
of the University of Amsterdam (Amsterdam, The Netherlands). Per sample, 0.5μg total 
RNA was amplified and combined with Spike A according to the Agilent Two-Color 
Microarray-Based Gene Expression Analysis kit (Agilent technologies). As a common 
reference sample an equimolar pool of all test samples was made and 0.5μg samples were 
amplified similarly as the test samples with the exception that Spike B was used. Amino-
allyl modified nucleotides were incorporated during the aRNA synthesis (2.5mM of each 
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GTP, ATP, UTP (GE Healthcare), 0.75mM CTP (GE Healthcare), 0.3mM AA-CTP 
(TriLink Biotechnologies)). Synthesized aRNA was purified with the E.Z.N.A. MicroElute 
RNA Clean Up Kit (Omega Bio-Tek). The quality was inspected on the BioAnalyzer 
(Agilent Technologies) with the Agilent RNA 6000 kit (Agilent Technologies). Test 
samples were labeled with Cy3 and the reference sample was labeled with Cy5. Five μg of 
aRNA was dried out and dissolved in 50mM carbonate buffer pH 8.5. Individual vials of 
Cy3/Cy5 from the mono-reactive dye packs (GE Healthcare) were dissolved in 200μl 
DMSO. To each sample, 10μl of the appropriate CyDye dissolved in DMSO was added 
and the mixture was incubated for 1h. Reactions were quenched with the addition of 5μl
4M hydroxylamine (Sigma-Aldrich). The labeled aRNA was purified with the E.Z.N.A. 
MicroElute RNA Clean Up Kit. Yields of aRNA and CyDye incorporation were measured 
on the NanoDrop ND-1000.
Microarray hybridization, scanning & data processing 
Each hybridization mixture was made up from 825ng Test (Cy3-labeled) and 825ng 
Reference (Cy5-labeled) material. Hybridization mixtures were using the Agilent Two-
Color Microarray-Based Gene Expression Analysis kit according to the manufacturer’s 
instructions (Agilent technologies). The samples were loaded onto the microarray chips 
and hybridized for 17h at 65 C. Afterwards the slides were washed and scanned (20 bit, 
3μm resolution) in an ozone-free room with the Agilent G2505C scanner. Data was 
extracted with Feature Extraction (v10.7.3.1, Agilent Technologies) with the 
GE2_107_Sep09 protocol for two-color Agilent microarrays. The Agilent output from the 
16 hybridizations was then imported into the Rosetta Resolver 7.2 software (Rosetta 
Biosoftware, Seattle, Washington) and subjected to a factorial design with a re-ratio with 
common reference application. Data analysis was performed setting cutoff for the p-value 
of <10-5 and for fold change of either >2 or <-2.
Gene Ontology analysis 
Gene Ontology analysis was performed with the PathVisio version 2 software 
(www.pathvisio.org [49]), setting cutoffs for p-value of <10-5 and for fold change of either 
>2 or <-2. For probe annotation, the Ensembl gene ID codes (ENSDARG) were used (see 
http://www.ensembl.org). The Z-scores shown correspond to a standard statistical test 
under the hypergeometric distribution. A high Z-score corresponds to a high level of 
enrichment of genes from a specific pathway in the investigated gene cluster.
Statistical analysis 
Statistical analyses (two-way ANOVAs with Bonferroni post-hoc tests) were performed 
using the GraphPad Prism version 4.00 (GraphPad Software, La Jolla, USA). 
Results 
The effect of GC treatment on amputation-induced leukocyte migration  
Previous studies in zebrafish larvae have shown that leukocytes migrate to wound sites 
which represents an inflammatory response and that this response is impaired upon 
treatment with GCs [41, 45]. In order to study this in detail, we set up a tail fin amputation 
assay using 3 day post fertilization (dpf) larvae that were first exposed to either vehicle or 
the synthetic GC beclomethasone (25μM) for 2h. Tail fins were then amputated and 




16 and 24h post amputation (hpa) and neutrophils and macrophages were labeled and 
counted. To determine the number of cells migrated to the wounded area, cells posterior to 








Figure 1. Schematic drawings of a zebrafish larvae at 3dpf (CV = caudal vein, YE = yolk 
extension). A. The site of the tail fin amputation. The red dashed line indicates where the cut in the 
tail was made.  B. The area used to determine the number of neutrophils and macrophages that had 
migrated to the wounded area. The dashed box indicates the area selected for counting. (C) The 
area that is used to determine the total amount of neutrophils and macrophages present in the entire 
tail region. The dashed box indicates the area selected for counting. 
 
 
Figure 2. Leukocyte staining upon tail fin amputation in a 3dpf embryo. A. Staining of all 
leukocytes by immunohistochemistry against the pan-leukocyte marker L-plastin (shown in red). 
B. Staining of neutrophils specifically by Mpx staining (shown in black). Neutrophils are stained 
by both methods, but the L-plastin immunolabeling is hard to detect in these cells due to the dark 
staining of the Mpx assay. Therefore, the number of neutrophils was determined by counting in the 
cells stained by the Mpx assay (shown black in A and B) and the number of macrophages was 
determined by counting the number of cells stained by the L-plastin immunohistochemistry (shown 
red in A). Cells posterior to the caudal vein were considered to have migrated, so this area (marked 
by the dashed red box) was used for cell counting.  
In order to label the populations of neutrophils and macrophages in 3dpf larvae we 
employed Myeloperoxidase (Mpx) histochemistry (specifically staining neutrophils [29]), 




development two populations of leukocytes are present: neutrophils, which are Mpx- and 
L-plastin-positive, and macrophages, which are Mpx-negative and L-plastin-positive [27,
29-31, 50]. The number of macrophages was therefore determined by counting the number 
of cells stained by the L-plastin immunostaining and not stained by the Mpx 
histochemistry, and the number of neutrophils was determined by counting cells stained by 
the Mpx assay (although they are stained by both methods, the L-plastin immunolabeling 





































Figure 3. The effect of beclomethasone treatment on leukocyte migration upon tail fin amputation 
in 3dpf zebrafish larvae. A. The number of neutrophils in the wounded area as a function of time 
after amputation. Statistical analysis by two-way ANOVA revealed that both beclomethasone 
treatment and time had a significant effect on the number of neutrophils (both p<0.001), and that 
the neutrophil number was significantly increased at 4hpa compared to the 0hpa time point 
(p<0.001). B. The number of macrophages in the wounded area as a function of time after 
amputation. Statistical analysis by two-way ANOVA revealed a migratory response of 
macrophages over time (p<0.001), but that beclomethasone did not have an effect.  
 
The results of this experiment revealed that both neutrophils and macrophages 
migrate towards the wound site, but that their migratory behavior and response to 
beclomethasone are remarkably different. Analysis of our data revealed a migratory 
response of neutrophils over time which was inhibited by beclomethasone treatment (as 
shown by a significant effect of time and beclomethasone treatment in a two-way ANOVA 
(both p<0.001)). Neutrophil migration reached a peak at 4hpa (7.4 ± 2.0 cells compared to 
0.6 ± 0.1 at 0hpa) and rapidly decreased after this time point to 3.4 ± 0.6 at 8hpa after 
which it remained stable at this level until 24hpa (Fig. 2). Beclomethasone treatment had a 
significant inhibitory effect on the neutrophil migration at 4hpa (4.3 ± 0.4 cells in the 
presence of beclomethasone). For macrophages, a migratory response was observed as 
well (p<0.001), but no effect of beclomethasone treatment was observed. Macrophage 
migration also increased rapidly, especially in the first 2 hours (9.7 ± 0.2 at 2hpa versus 
4.0 ± 0.1 0hpa), but no decline was observed afterwards. In addition, macrophages 
migrated more to the posterior end of the tail where they appeared to line up at the actual 
wound site, whereas neutrophils were more randomly located in the vicinity of the wound 
(for representative pictures, see Fig. 2). Based on these results, we concluded that both 
neutrophils and macrophages migrate towards wound sites, but that beclomethasone 
exhibits an inhibitory effect only on neutrophil migration. 
Subsequently, higher doses of beclomethasone were tested for their inhibitory role 
on neutrophils and macrophages at 4hpa. These doses did not induce effects on migration 




shown), indicating that at this dose a maximal effect had already been reached. In order to 
establish that beclomethasone specifically impairs the migration of neutrophils rather than 
their total number, cells in the entire tail fin area (posterior to the yolk extension) were 
counted (Fig. 1C). The results of these countings did not show any significant difference in 
the number of neutrophils between vehicle- and beclomethasone-treated larvae upon 
amputation (Suppl. Fig. 1), indicating a specific effect of beclomethasone on the neutrophil 
migration towards wound sites. 
 
Design of the microarray experiment 
Next we wanted to investigate the effect of beclomethasone treatment on amputation-
induced changes in gene expression at the whole transcriptome level by microarray 
analysis. For that reason, we employed the tail fin amputation assay described above, 
collecting total RNA samples at 4hpa. Four experimental groups were generated: control 
(non-amputated) treated with vehicle (con/vehicle), control treated with beclomethasone 
(con/beclo), amputated treated with vehicle (4hpa/vehicle) and amputated treated with 
beclomethasone (4hpa/beclo). Subsequently, the RNA samples from these experimental 
groups were used in a microarray experiment and the data were analyzed using the Rosetta 
Resolver 7.2 software, setting signatures for significantly regulated probes at a p-value 
cutoff of p <10-5 and fold changes either >2 or <-2. Gene annotation and probe assignment 
was performed based on the Ensemble Gene ID codes (ENSDARG). 
 
The effects of amputation on gene transcription  
First, we identified 1403 probes to be significantly regulated due to amputation 
(comparison con/vehicle vs. 4hpa/vehicle). Gene annotation demonstrated that these 
probes corresponded to 585 genes, of which 410 were upregulated and 175 downregulated 
due to amputation. Gene ontology analysis (using PathVisio software) revealed that mainly 
immune-related signaling routes were affected like the Toll-like, NOD-like and RIG-I-like 
receptor pathway, the Prostglandin, Cytokine, Interferon, and Jak-STAT signaling 
pathways as well as Eicosanoid synthesis (Suppl. Table 1). 
 
The effects of beclomethasone treatment on amputation-induced gene transcription  
Subsequently, as a first readout of the effect of beclomethasone treatment on amputation-
induced changes in gene expression, we studied how amputation-regulated genes generally 
respond to beclomethasone treatment. Therefore, for each of the 1403 probes that were 
significantly regulated by amputation we plotted the fold change due to beclomethasone 
treatment in amputated larvae (comparison 4hpa/vehicle vs. 4hpa/beclomethasone) as a 
function of the fold change due to amputation (comparison con/vehicle vs. 4hpa/vehicle). 
In the resulting scatter plot (Fig. 4) probes representing genes that are upregulated by 
amputation and of which this upregulation is enhanced in the presence of beclomethasone 
are shown in the upper right quadrant (164 probes representing 69 genes). Probes 
representing genes that are upregulated by amputation and of which this upregulation is 
attenuated by beclomethasone are presented in the lower right quadrant (876 probes, 349 
genes). Interestingly, this plot demonstrates that the vast majority of probes/genes that are 
upregulated by amputation shows an attenuation of this upregulation in the presence of 
beclomethasone. This majority contains 84% of the probes and 83% of the genes showing 
upregulation by amputation. A similar effect was observed upon studying the probes that 
showed downregulation by amputation. Of these probes, 92% (363 probes representing 
164 genes) displayed an attenuation of this downregulation in the presence of 
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beclomethasone and is shown in the upper left quadrant, whereas only a small number 










-7 -6 -5 -4 -3 -2 -1/1 2 3 4 5 6 7

















↑ 4hpa, ↓ beclo
876 probes (349 genes)
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164 probes (69 genes)
↓ 4hpa, ↑ beclo
363 probes (164 genes)
↓ 4hpa, ↓ beclo
32 probes (14 genes)
Figure 4. Scatter plot showing the effect of beclomethasone treatment on amputation-induced 
alterations in gene expression. For all 1403 probes showing significant regulation upon amputation 
(comparison con/vehicle vs. 4hpa/vehicle), the fold change due to beclomethasone treatment in 
amputated larvae (4hpa/vehicle vs. 4hpa/beclo) was plotted as a function of the fold change due to 
amputation. This plot shows that beclomethasone has a very general attenuating effect on 
amputation-induced gene regulation. Of the 1040 probes showing upregulation by amputation, 
84% shows a suppression of this regulation in the presence of beclomethasone (lower right 
quadrant), and of the 385 probes showing downregulation in response to amputation, 92% shows 
an attenuated downregulation upon beclomethasone treatment (upper left quadrant). The grey 
dashed line indicates the point at which beclomethasone treatment completely abolishes 
amputation-induced changes, showing that in the vast majority of cases beclomethasone dampens 
the effects of amputation on gene expression, but does not block them entirely. 
The grey dashed line in the scatter plot indicates the point at which the regulation 
by amputation is completely abolished by beclomethasone. Obviously, most of probes in 
the right lower quadrant are located above this line, indicating that in the majority of cases 
GC treatment attenuates the amputation-induced gene upregulation, and that it does not 
completely block it. In the left upper quadrant, a similar effect is shown for the probes 
downregulated upon amputation. The majority of probes is located below the grey line, 
indicating that GC treatment does not totally eliminate the amputation-induced 
downregulation. Taken together, these data show that beclomethasone treatment has a very 
general attenuating effect on amputation-induced alterations in gene expression, thereby 
dampening (rather than abolishing) these effects. 
Next, we were interested in which individual beclomethasone-induced changes in 




significantly upregulated by amputation, and found that 94 of these genes (23%) displayed 
a beclomethasone-induced attenuation of this upregulation that reached significance (Fig. 
5A). We subsequently looked at the set of 175 genes downregulated by amputation and 19 
genes (11%) showed a beclomethasone-induced attenuation of the downregulation that 
reached significance (Fig. 5B).  
From the cluster of 94 genes that showed a significant upregulation by amputation 
that was attenuated by beclomethasone, we decided to validate by qPCR the expression of 
il8, il1b, mmp9, mmp13a tnfa and ptgs2b. The results demonstrated that 4 of the genes we 
tested (il8, il1b, mmp9, mmp13a) showed a significant induction due to amputation which 
was then significantly impaired in the presence of beclomethasone (Fig. 6). The other 2 
genes (tnfa and ptgs2b) did not display significant regulation by either amputation or 
beclomethasone, but a trend showing upregulation due to tail fin injury and GC-mediated 
attenuation of this effect is present (Fig. 6).  
Further gene ontology analysis on this cluster of 94 genes revealed that the 
majority of the signaling pathways involved were identical to those regulated by 
amputation (immune-related signaling cascades like the Toll-, RIG-I- and NOD-like 
receptor, Jak-STAT, and Cytokine signaling and Eicosanoid synthesis pathways (Suppl. 
Table 2)), indicating that beclomethasone treatment affects virtually all amputation-
induced signalimng pathways. Since the Toll-like receptor pathway was represented by a 
relatively large number of genes (12) in this cluster of 94 genes, we studied the alterations 
in this pathway in more detail. The results showed that the only Toll-like receptor gene 
present in this cluster was tlr5a. In addition, 3 genes encoded subunits of the AP-1 
complex (fos, junb, atf3), suggesting an important role for this transcription factor in 
mediating the attenuation of amputation-induced gene regulation by beclomethasone. Six 
genes corresponded to cytokines (il1b, il8, il12a, ifn, tnfa, cxcl-c1c), and two genes to 
other pro-inflammatory mediators (ptgs2b, mmp9) that are known to be induced upon 
activation of the Toll-like receptor pathway. 
 
156 19 418
con/vehicle > 4hpa/vehicle 4hpa/vehicle < 4hpa/beclo
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316 94 264




Figure 5. Venn diagrams showing the identification of the cluster of genes significantly regulated 
by amputation, and showing significant attenuation of this regulation in the presence of 
beclomethasone. A. Genes significantly upregulated due to amputation (410) are shown in the grey 
circle and genes significantly downregulated by beclomethasone treatment in amputated larvae 
(358) are shown in the white circle. The overlap represents the cluster of 94 genes of which the 
amputation-induced upregulation is attenuated by beclomethasone. B. Genes significantly 
downregulated due to amputation (175) are shown in the grey circle and genes significantly 
upregulated by beclomethasone treatment in amputated larvae (437) are shown in the white circle. 
The overlap represents the cluster of 19 genes of which the amputation-induced downregulation is 































































































































Figure 6. Validation by qPCR of 6 genes (il8, il1b, mmp9, mmp13a, tnfa and ptgs2b) that showed 
a significant upregulation by amputation that was attenuated by beclomethasone. The relative 
mRNA concentrations were normalized to those of Bactin1 and the values shown are the means ± 
s.e.m. of four independent experiments. Statistical analysis demonstrated that beclomethasone 
attenuated the amputation-induced upregualtion of il8, il1b, mmp9 and mmp13a. The other genes 
(tnfa, ptgs2b) did not reach significance for their induction by amputation (although the trend is 
present), but in the case of ptgs2b, beclomethasone treatment of amputated embryos led to a 
significant suppression compared to vehicle treated embryos. For tnfa, the GC-mediated 
attenuation did not reach significance. Asterisks (*) correspond to a statistical significance of p 
<0.05 compared to con/vehicle groups. Key symbols (#) correspond to a statistical significance of 
p <0.05 compared to 4hpa/vehicle groups. 
 
The effects of beclomethasone on gene transcription  
Furthermore, we investigated which genes responded to beclomethasone treatment in non-
amputated larvae. A cluster of 2184 probes was identified to be significantly regulated due 
to beclomethasone treatment (comparison con/vehicle vs con/beclo). Gene annotation 
demonstrated that these probes corresponded to 815 genes, of which 606 were upregulated 
and 209 downregulated due to beclomethasone. Gene ontology analysis revealed specific 
signaling routes to be affected such as those involved in lipid metabolism (e.g. PPAR and 
adipocytokine signaling and bile acid synthesis pathways) alongside immune-related (e.g. 
NOD-like receptor and prostaglandin pathways) as well as non-immune related pathways 
(e.g. DNA replication and sulfur metabolism (Suppl. Table 3)).
Next, we were interested in genes which were significantly changed due to 
beclomethasone treatment of amputated larvae (comparison 4hpa/vehicle vs. 4hpa/beclo). 
We identified 2076 probes to be significantly regulated and gene annotation revealed that 




downregulated. Gene ontology analysis demonstrated that lipid-related cascades (e.g. 
PPAR signaling and bile acid synthesis pathways) as well as immune-related ones (e.g. 
Toll-like receptor, prostaglandin signaling and natural killer cell-mediated toxicity 
pathways) were again affected, alongside phagosome and VEGF signaling pathways 
(Suppl. Table 4). From these 795 genes, 113 were previously identified to be regulated by 
amputation and subsequently affected due to beclomethasone treatment (Fig. 5). 
Additionally, 241 (30%) of these genes were found to be regulated by beclomethasone in 
non-amputated embryos as well. This latter cluster verifies the validity of our microarray 






In the present study, we have used zebrafish larvae in order to study the effects of GC 
signaling on the inflammatory response to tail fin amputation, both at the cellular and the 
molecular level. It is well known that upon wounding chemotactic cues attract both 
neutrophils and macrophages to the wound site in order to combat microbes [51]. In our 
study, visual detection of macrophages and neutrophils (the former defined as L-plastin-
positive and mpx-negative cells, the latter as L-plastin- and mpx-positive [27, 29-31, 50]) 
revealed that both cell types started to be recruited to the wound site as early as 2hpa. At 
this time point, macrophage recruitment reached a level which sustained for at least 
another 22h. Neutrophil migration reached a peak at the 4hpa time point after which their 
number declined, but remained elevated above basal levels for another 20h (Fig. 3). 
Previous studies employing similar tissue wounding in zebrafish larvae showed that 
macrophages [52] and neutrophils [29, 53-55] migrated to the wound sites. In two recent 
studies [56, 57], the time course of the recruitment of both macrophages and neutrophils to 
wound sites in the tail fin was studied as well and the results are in line with those from 
our study. In both studies, neutrophil accumulation at the wounded tissue peaked at around 
6hpa, after which numbers declined to baseline, and macrophage migration increased 
rapidly over the first 6 hours as well and remained at a high level until 48 hpa. In our 
study, macrophage recruitment appears to be more rapid, reaching a plateau already at 2 
hpa, but different ways to define and count the population of macrophages (L-plastin 
immunohistochemistry in our study versus fms:Gal4/UAS:mCherry transgenic fish [56] 
and neutral red staining [57]) may underlie the observed differences.  
We next examined the effect of GC treatment on the migration of leukocytes 
towards injured sites. Our analysis showed that beclomethasone treatment had a significant 
inhibitory effect only on the migration of neutrophils but not on that of macrophages (Fig. 
3). These results are in line with previously observed GC effects on leukocytes in 3dpf 
zebrafish larvae that were shown to be specifically suppressive regarding the recruitment 
of neutrophils towards wounded tissue but not that of macrophages [45]. Hence, the 
zebrafish model recapitulates the inhibitory effects of glucocorticoids on neutrophil 
migration towards inflamed tissues, that have been well established in mammalian models 
[58]. As for macrophages, studies in mammalian models have shown that GCs can 
suppress the migratory properties both in vitro [59] and in vivo [60]. Whether the 
resistance to GC treatment of macrophages observed in the zebrafish model is specific for 
fish in general, or the result of the developmental stage of the larvae, the time frame of the 
assessments, or the selected tissue remains to be investigated.  
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Subsequently, we evaluated the changes in gene expression that are associated with 
amputation and beclomethasone treatment. First, we looked for transcriptional changes 
4hpa and we identified 585 genes of which the expression was significantly altered upon 
amputation. These genes are mainly involved in immune-related signaling routes such as 
that of Toll-like, NOD-like and RIG-I-like receptors, as well as Jak-STAT and cytokine 
signaling, and Prostaglandin, Interferon, and Eicosanoid synthesis (Suppl. Table 1). Since 
we used whole larvae for our transcriptional analysis, it must be noted that we do not know 
in which cell type the induced expression occurs. However, in other studies, it was shown 
that amputation-induced upregulation of pro-inflammatory genes like mmp9 and junb was 
mainly observed in the epithelium at the wound site (Mathew 2007, Yoshinari 2009), 
suggesting that most of the observed amputation-induced alterations in gene expression 
arise in the tissue around the wound site and not in the immune cells. In a similar study by 
Yoshinari et al. [61], in which 2dpf embryos were tail fin amputated and samples were 
collected at a much later time point (16hpa), transcriptome analysis revealed that the 
largest fraction of regulated signaling routes were metabolic pathways (40%) and only a 
small fraction (2%) of signaling cascades regulated were immune-related. These results 
suggest that the time after injury is an important determinant for the alterations in gene 
transcription that can be observed. Thus, it appears that at 4 hours after injury, immune-
related pathways are heavily activated at the transcriptional level, while 12 hours later 
amputation-induced changes in gene expression no longer reflect an inflammatory 
response, which is in line with the observed decline in neutrophil migration and the plateau 
that has been reached in macrophage recruitment at this time point. Most likely, at this 
stage, the transcriptional response has probably shifted towards the stimulation of 
regenerative processes.  
Second, we were interested in how beclomethasone affected the expression of these 
amputation-regulated genes. Hence, we plotted for each of the 1403 probes that showed a 
significant regulation upon amputation the fold change due to beclomethasone treatment in 
amputated larvae as a function of the fold change due to amputation (Fig. 4). This analysis 
revealed that the vast majority (83%) of amputation-induced genes showed an attenuated 
induction in the presence of beclomethasone. Similarly, 94% of the amputation-
downregulated genes displayed an attenuation of this downregulation in the presence of 
beclomethasone (Fig. 4). It must be noted that our data show that in general the 
transcriptional responses to tail fin injury are not completely blocked by beclomethasone, 
but that they are dampened. Thus, in this model GCs appear to have a suppressive effect 
on virtually all changes in gene transcription at 4hpa, which are mainly pro-inflammatory 
in nature, indicating that GCs have a general immunosuppressive effect without any 
apparent specificity for particular gene networks.  
Ninety-four genes were identified for which both the induction by amputation and 
the beclomethasone-induced attenuation of this induction reached significance (and 19 
genes for which the suppression upon amputation and the attenuation of this suppression 
by beclomethasone was significant). Gene ontology analysis revealed that within this 
cluster of 94 genes, immune-related signaling routes were overrepresented, like the Toll-,
RIG-I- and NOD-like receptor, Jak-STAT and cytokine signaling and Eicosanoid synthesis 
pathways. In this gene cluster we found many well-known pro-inflammatory agents, which 
have been demonstrated to be suppressed upon GC treatment, such as il8, il1b, tnfa, il11a, 
il12a, mmp9, mmp13a and ptgs2b (which is the orthologue of the human cox-2 gene) [10,
62-66]. For the majority of these genes, it has been well established that DNA-binding-
independent transrepression takes place via interaction of GR and immune-related 




model of wound-induced inflammation recapitulates the anti-inflammatory GC effects 
with respect to gene transcription observed in mammalian systems, and we therefore 
suggest that this model system could be further developed as a screening assay for novel 
GC drugs. 
Interestingly, we also found 3 genes encoding AP-1 subunits (fos, junb, atf3) in the 
above mentioned cluster of 94 genes, indicating that, under our experimental conditions, 
the activity of AP-1 is inhibited by GCs through a decrease in the expression level of 
several AP-1 subunits. This finding supports an important role for this transcription factor 
in mediating the attenuation of amputation-induced gene regulation by beclomethasone in 
zebrafish larvae. A cross-talk (leading to transrepression of pro-inflammatory genes) 
between GR and AP-1 signaling has been extensively reported to occur via a physical 
interaction of GR and the c-Jun subunit of AP-1 complex as well as via GR-mediated 
inhibition of c-Jun activation [67-69]. The downregulation of the expression level 
observed in our study illustrates that an additional molecular mechanism of negative cross-
talk between AP-1 and GR occurs in vivo. 
Finally, 815 genes were identified that significantly responded to beclomethasone 
treatment in non-amputated larvae. These genes were attributed to specific signaling routes 
such as those involved in lipid metabolism (e.g. PPAR and adipocytokine signaling and 
bile acid synthesis pathways) alongside immune-related (e.g. NOD-like receptor and 
prostaglandin pathways) as well as non-immune related pathways (e.g. DNA replication 
and sulfur metabolism (Suppl. Table 3)). Similarly, we identified 795 genes to be 
significantly changed due to beclomethasone treatment of amputated larvae that gene 
ontology analysis revealed that lipid-related cascades (e.g. PPAR signaling and bile acid 
synthesis pathways) as well as immune-related ones (e.g. Toll-like receptor, prostaglandin 
signaling and natural killer cell-mediated toxicity pathways) were again affected, alongside 
phagosome and VEGF signaling pathways (Suppl. Table 4). A cluster of 241 genes was 
found to be regulated by beclomethasone in both amputated and non-amputated larvae. 
This latter cluster is apparently robustly regulated by GCs, and could therefore provide a 
reference set of marker genes for studying GR signaling in zebrafish larvae.  
In summary, the zebrafish embryonic model of tail fin amputation and GC 
treatment constitutes a reliable system for studying GR signaling with respect to the innate 
immune response. In particular, we observed that both macrophages and neutrophils 
migrated to inflamed tissues and that this course was hindered by GC treatment only in the 
case of neutrophils. Furthermore, amputation resulted in activation of various immune-
related signaling cascades for which GR activation had a general immunosuppressive 
effect, lacking any apparent specificity for particular signaling cascades. We suggest that 
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Supplemental Figure 1. Neutrophils present in the entire tail region (posterior to the yolk 
extension, area marked by the dashed red box in Fig. 1C) compared to neutrophils present in the 
area close to the wound (posterior to the caudal vein, area marked by the dashed red box in Fig. 
1B). Larvae were treated with either vehicle (white bars) or 25μM beclomethasone (grey bars). 
Statistical analysis showed that beclomethasone does not affect the number of neutrophils present 
in the entire tail region, but only the number of cells localized in the area close to the wound. The 
asterisk (*) corresponds to a statistically significant difference in area close to the wound compared 
to vehicle treatment (p<0.05). 
 
Supplemental Table 1: Pathways enriched in cluster of 585 genes regulated upon amputation, 
determined by gene ontology analysis using PathVisio software (p-value cutoff <10-5, fold change 
>2 or <-2). * Reference set based on Mycobacterium marinum yolk infection. 
Pathway Genes meeting criteria Z score
Response to infection * 39 10.31
Toll-like receptor pathway 22 7.05
Prostaglandin signaling 7 4.86
Cytokine-cytokine receptor interaction 12 3.41
Jak-STAT signaling pathway 10 3.27
Eicosanoid Synthesis 3 3.2
NOD-like receptor signaling pathway 6 3.18
RIG-I-like receptor signaling pathway 6 2.92
Pantothenate and CoA biosynthesis 2 2.68





Supplemental Table 2: Pathways enriched in cluster of 94 genes that showed an upregualtion 
by amputation, which was attenuated by beclomethasone, determined by gene ontology analysis 
using PathVisio software (p-value cutoff <10-5, fold change >2 or <-2). * Reference set based on 
Mycobacterium marinum yolk infection. 
 
Supplemental Table 3: Pathways enriched in gene cluster (815 genes) regulated by 
beclomethasone, determined by gene ontology analysis using PathVisio software (p-value cutoff 
<10-5, fold change >2 or <-2). * Reference set based on Mycobacterium marinum yolk infection. 
 
Supplemental Table 4: Pathways enriched in gene cluster (795 genes) regulated by 
beclomethasone in amputated larvae, determined by gene ontology analysis using PathVisio 
software (p-value cutoff <10-5, fold change >2 or <-2). * Reference set based on Mycobacterium 







Pathway Genes meeting criteria Z score 
Response to infection * 16 9.07 
Toll-like receptor pathway 12 8.78 
Eicosanoid Synthesis 2 4.73 
Cytokine-cytokine receptor interaction 6 4.33 
RIG-I-like receptor signaling pathway 4 3.72 
NOD-like receptor signaling pathway 3 3.71 
Arachidonic acid metabolism 2 3.15 
Cytosolic DNA-sensing pathway 2 3.15 
Jak-STAT signaling pathway 4 3.06 
Pantothenate and CoA biosynthesis 1 2.88 
Pathway Genes meeting criteria Z score 
Primary bile acid biosynthesis 4 5.11 
NOD-like receptor signaling pathway 8 4.49 
PPAR signaling pathway 9 4.35 
Prostaglandin signaling 6 3.81 
Response to infection* 21 3.8 
Nuclear receptors in lipid metabolism and toxicity 4 3.36 
NOD pathway 7 3.14 
Sulfur metabolism 2 3.08 
DNA Replication 4 2.35 
Adipocytokine signaling pathway 6 2.12 
Pathway Genes meeting criteria Z score 
PPAR signaling pathway 12 5.25 
Toll-like receptor pathway 21 4.98 
Prostaglandin signaling 8 4.59 
Natural killer cell-mediated cytotoxicity 12 4.03 
Response to infection* 23 3.18 
Primary bile acid biosynthesis 3 3.08 
NOD pathway 8 3.01 
Taurine and hypotaurine metabolism 2 2.91 
Phagosome 14 2.64 
VEGF signaling pathway 9 2.64 
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Supplemental Table 5: Sequences of all primers used for qPCR analysis. 
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The glucocorticoid receptor (GR) regulates gene expression upon binding to 
glucocorticoid (GC) hormones. In humans and zebrafish, two GR splice variants exist: the 
		&-isoform 2&)	
-activated transcription factor, and the GR 
-isoform 2&, which has been shown to have a dominant-
+	
&, !n
the present study we have used the zebrafish model system in order to reveal genes 
affected by each of these two receptor isoforms. Zebrafish embryos were injected at the 1-
2 cell stage with two splice-blocking antisense oligos (one leading to knockdown of both 
&- -isoforms, and another targeting the alternative splicing of the GR pre-mRNA 
 +  
 & -*  
 & *&3$ 2
  		 &
overexpression). Embryos were treated with the synthetic GC dexamethasone and 
transcriptome analysis was performed using microarray technology and subsequent qPCR 
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of genes mainly involves cell-cycle-related genes, whereas the second cluster of genes
mainly contains genes involved in metabolism. Furthermore, our data do not support a 
	
  & dominant negative inhibitor of &. However, &	
have an intrinsic transcriptional activity that would, nevertheless, require high expression 
levels of this splice variant. 
Introduction
The glucocorticoid receptor (GR) is expressed almost ubiquitously in the human body and 
regulates a wide range of biological processes such as our metabolism, growth, 
reproduction, vascular tone, bone formation, immune response and brain function [1-6]. In 
its inactive state, the GR mainly resides within the cytoplasm in a multiprotein complex 
containing chaperones and immunophilins. The GR is activated by binding of its cognate 
ligands (glucocorticoids (GCs)), and upon activation, it is released from its cytoplasmic 
complex and translocates to the nucleus, where it orchestrates gene expression via DNA-
binding-dependent and -independent mechanisms. DNA-binding-dependent mechanisms 
involve GR binding to glucocorticoid response elements (GREs), where it recruits 
transcriptional coregulators and thus, directs (positively or negatively) the transcription 
rate of target genes. Independent of DNA-binding, the GR can also physically interact with 
other transcription factors (e.g. NF-"#$%-1), via which it can either synergistically 
induce gene expression or repress activation of genes. The latter mode comprises one of 
the classical ways by which GCs exert their anti-inflammatory effects, which is the basis 
of their intensive clinical use in the treatment of immune-related diseases like asthma and 
rheumatoid arthritis [1, 2, 7-11]. 







the C-terminal end of the ligand binding domain (LBD). [12, 13], 6	) 
 & -
isoform (777 amino acids, representing the canonical receptor) is able to interact with GCs, 

&-isoform (742 amino acids) has a shorter LBD with a unique C-terminal 
15 amino acid sequence, which renders it unable to bind GCs [12-14]. Experimental data 















20]. However, the biological significance of hGR is still debated, mainly due to 
inconsistent results regarding its transcriptional role, [21-27] its low expression levels [15,
28, 29] and low level of evolutionary conservation [30, 31].
Over the last decade, the zebrafish has emerged in biomedical research as an
important model system for a variety of human diseases [32-34]. It is easily handled and 
maintained and produces big clutches of embryos, which are fertilized externally and 
develop rapidly [35]. Moreover, its genome has been sequenced and embryos can easily be 
subjected to genetic manipulations [35, 36]. Furthermore, the zebrafish has been 
considered as a potent model organism for GC research [37-40]. As humans, zebrafish 
have a single GR (zGR), and cortisol is the main endogenous GC. Its secretion is regulated 
by the hypothalamus pituitary interrenal (HPI) axis, which is the equivalent to the 
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as a result of alternative splicing [30, 44]. The zGR is highly similar to its human 
equivalent in structure, subcellular localization and expression level [30]. However, the 
 
  	 +
 ( 
 '  &  & are 
different between humans and zebrafish, suggesting that zGR and hGR have evolved 
independently [30].
In the present study we have used the zebrafish as an in vivo model to study the GR 
signaling pathway at the whole-organism level. A genetic manipulation approach of the 
zGR in zebrafish embryos was used in order to reveal responsive genes specific for the 
& -  -isoform in the absence of exogenous GCs (thus, studying zGR signaling 
under basal cortisol levels) as well as in the presence of exogenous GCs (thus, studying 
zGR signaling under elevated GC levels). We availed ourselves of the use of splice-
blocking morpholino antisense oligomers, which are widely used for studying gene 
function via impeding normal splicing, thus leading to knockdown of genes or altered 
regulation of alternative splicing during embryonic development [45]. By using a 







&*&3$)we aimed to 
identify specific clusters of target genes for both GR variants.
Materials & Methods
Zebrafish strain, husbandry & egg collection
Wild type adult ABxTL zebrafish were used in this study. Livestock was maintained and 
handled according to the guidelines from http://zfin.org. Fertilization was performed by 
natural spawning (single crossings) at the beginning of the light period and eggs were 
raised at 28C in E3  
 ** 	
 BDEg/ml Instant Ocean sea salts 
supplemented with 0.0025% methylene blue (GURR). All experimental procedures were 
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from Ambion. Newly synthesized mRNA was purified using the RNeasy MinEluteTM





60C for 5min and 
diluted at a final concentration of 5ng/El in 1x Danieu’s buffer (58mM NaCl, 0.7mM KCl,








Morpholinos preparations and injections 
In this study 3 different morpholinos were used (purchased from GeneTools), all of which 
prepared and stored according to the manufacturer’s instructions. Sequence for Standard 
Control morpholino (SC-MO): CCTCTTACCTCAGTTACAATTTATA. Sequence for 
morpholino targeted against the splice acceptor site of exon 8 of the zebrafish 
glucocorticoid receptor gene (MO1): TTTAGGAGAAGCATCATTACGTCGT. Sequence 
for moprholino targeted against the splice donor site of exon 2 of the zebrafish 
glucocorticoid receptor gene (MO2): GGTCTTGATGGCTTACCTGGAATAG. Prior to 
injections, morpholinos were diluted at a final concentration of 0.05mM in 1x Danieu’s 
buffer (58mM NaCl, 0.7mM KCl, 0.4mM MgSO4, 0.6mM Ca(NO3)2, 5mM HEPES at pH 
7.6) containing 0.05% phenol red (Sigma). Approximately 1nl of each morpholino solution 
was injected into the yolk of 1-2 cell stage fertilized eggs.
RT-PCR analysis of modified splicing of the glucocorticoid receptor upon morpholino 
injections
One hundred ng of DNAase treated total RNA samples were used as a template for one-
step RT-PCR analysis of zebrafish glucocorticoid receptor RNA sequences using the 
SuperScript® III One-step RT-PCT System with Platinum® Taq DNA Polymerase kit 
(Invitrogen) according to the manufacturer’s manual (setting annealing temperature at 
60C). Four different primer pairs were used: Pair 1: forward primer: TGTGAACA-
GATGTTGAAGATCTCCA, reverse primer: AAACATCCGTCTAGAGGCAA, Pair 2:
forward primer: TGTGAACAGATGTTGAAGATCTCCA, reverse primer: CTGGTGA-
AAGAGCAGCGGTTTA, Pair 3: forward primer: AGCTGTCGTCGGTCTGCAGAAA, 
reverse primer: GCAGGTTAGGGTAATTAGGCAAGT, Pair 4: forward primer: CAGG-
GGTCATCAAACAGGAGAA, reverse primer: GACAGATCTTGTGTGTGCCAGTCTT.
Glucocorticoid treatment of injected embryos 
Twenty-five hours post fertilization embryos injected with either SC-MO, MO1, MO1 or 





optimal comparison with the other groups) were placed in 2% agarose-coated Petri dishes, 
where they were incubated with 100EM dexamethasone (Sigma) in E3 medium for 6h at 
28C. Samples were collected in TRIzol® reagent (Invitrogen) and total RNA was isolated 
according to the manufacturer’s instructions (Invitrogen).
RNA isolation & cDNA synthesis 
Total RNA was extracted using the TRIzol® reagent (Invitrogen) according to the 




5min at 60C. Samples were treated with DNAase using the DNA-free™ kit (Ambion). 
For microarray analysis, RNA was further purified using the RNeasy MinEluteTM Cleanup 
kit from Qiagen and its integrity was checked with a lab-on-chip analysis using the 2100 
Bioanalyzer (Agilent Technologies). For subsequent cDNA synthesis, at least 250ng of 
total RNA was added as a template for reverse transcription using the iSCRIPTTM cDNA 
Synthesis Kit (Biorad). Non reverse-transcribed samples were also generated to be used as 
negative controls during the quantitative polymerase chain reaction step.
Quantitative Polymerase Chain Reaction (qPCR) 
qPCR analysis was performed using the MyiQ Single-Color Real-Time PCR Detection 
System (Biorad). PCR reactions were performed in a t
+*;E	
;E
of cDNA)El forward and reverse primer (10EM) and 12.5El of 2x iQ™ SYBR® Green 
Supermix (Biorad). Cycling conditions were 95C for 3min, followed by 40 cycles of 15 
sec at 95C, 30 sec at 60C and 30sec at 72C. Ct values (cycle number at which a 
threshold value of the fluorescence intensity was reached) were determined for each 
sample. A dissociation protocol was added, determining dissociation of the PCR products 
from 65C to 95C, allowing discrimination of specific products. In order to determine the 
efficiency of the amplification reaction, serial dilutions of cDNA were used and standard 
curves were generated plotting the Ct values against the relative cDNA concentration. The 
linear slope of the standard curve for each primer pair was determined and the efficiency 




 . This was done for 
the target gene and a reference gene.  Finally, the Ct value was determined by subtracting 
the Ct value of the experimental sample from the Ct value of a control sample, and the fold 














arg . In all qPCR experiments, a non reverse 
transcribed sample and a water-control were included. All cDNA samples were assayed in 
duplicate. Values shown are means ± s.e.m of three individual experiments. Sequences of 
all primers used for qPCR analysis are included in Suppl. Table 4.
Microarray design
A 4x180k microarray chip platform (customized by Agilent Technologies, (Design 
ID:028233)) was used in this study. This array consists of all probes already present in an 
earlier 45.219 custom-made array [46], and another 126.632 newly designed zebrafish 
probes had been added as described in [47]. A total of 24 samples (8 experimental groups 
from 3 replicate experiments) were processed for transcriptome analysis. On each 4x180k 
slide, 4 random samples from different replicate experiments were hybridized against a 
common reference.
Microarray amplification & labeling
Amplification and labeling of RNA was performed at the MicroArray Department (MAD) 
of the University of Amsterdam (Amsterdam, The Netherlands). Per sample, 0.5Eg total 
RNA was amplified and combined with Spike A according to the Agilent Two-Color 
Microarray-Based Gene Expression Analysis kit (Agilent technologies). As a common 
reference sample an equimolar pool of all test samples was made and 0.5Eg samples were 
amplified similarly as the test samples with the exception that Spike B was used. Amino-
allyl modified nucleotides were incorporated during the aRNA synthesis (2.5mM of GTP, 
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ATP, and UTP (GE Healthcare), 0.75mM CTP (GE Healthcare), 0.3mM AA-CTP 
(TriLink Biotechnologies)). Synthesized aRNA was purified with the E.Z.N.A. MicroElute 
RNA Clean Up Kit (Omega Bio-Tek). The quality was inspected on the BioAnalyzer 
(Agilent Technologies) with the Agilent RNA 6000 kit (Agilent Technologies). Test 
samples were labeled with Cy3 and the reference sample was labeled with Cy5. 4+Eg of 
aRNA was dried out and dissolved in 50mM carbonate buffer pH 8.5. Individual vials of 
Cy3/Cy5 from the mono-reactive dye packs (GE He
	  +  DDE
.F=@,	*)DEl of the appropriate CyDye dissolved in DMSO was added




4M hydroxylamine (Sigma-Aldrich). The labeled aRNA was purified with the E.Z.N.A. 
MicroElute RNA Clean Up Kit. Yields of aRNA and CyDye incorporation were measured 
on the NanoDrop ND-1000.
Microarray hybridization, scanning & data processing 
Each hybridization mixture was made up from 825ng Test (Cy3-labeled) and 825ng 
Reference (Cy5-labeled) material. Hybridization mixtures were using the Agilent Two-
Color Microarray-Based Gene Expression Analysis kit according to the manufacturer’s 
instructions (Agilent technologies). The samples were loaded onto the microarray chips 
and hybridized for 17h at 65C. Afterwards the slides were washed and scanned (20 bit, 
3μm resolution) in an ozone-free room with the Agilent G2505C scanner. Data was 
extracted with Feature Extraction (v10.7.3.1, Agilent Technologies) with the 
GE2_107_Sep09 protocol for two-color Agilent microarrays. The Agilent output from the 
16 hybridizations was then imported into the Rosetta Resolver 7.2 software (Rosetta 
Biosoftware, Seattle, Washington) and subjected to a factorial design with a re-ratio with 
common reference application. Data analysis was performed setting cutoff for the p-value 
of <10-10 and for fold change of either >2 or <-2.
Gene Ontology analysis 
Gene Ontology analysis was performed with the PathVisio version 2 software 
(www.pathvisio.org [4]), setting cutoffs for p-value of <10-10 and for fold change of either 
>2 or <-2. For probe annotation, the Ensembl gene ID codes (ENSDARG) were used (see 
http://www.ensembl.org). The Z-scores shown correspond to a standard statistical test 
under the hypergeometric distribution. A high Z-score corresponds to a high level of 
enrichment of genes from a specific pathway in the investigated gene cluster.
Statistical analysis
Statistical analyses (t-tests and ANOVAs with Bonferroni post-hoc tests) were performed 
using the GraphPad Prism version 4.00 (GraphPad Software, La Jolla, USA). For results in 
Fig. 2 and Fig. 9 statistical analysis was performed on log10 transformed data. 
Results
Analysis of zGR splice-blocking morpholino effects
In order to downregulate the expression of the & 
	
  
 that of 
&, we designed a splice-blocking morpholino targeted against the splice donor site of 




increased production  
 & -isoform and simultaneously towards a decreased 























Figure 1. Schematic overview of the location of the target sites of zGR splice-blocking 
morpholinos MO1 (A) and MO2 (B). Primers used to analyze the effect of the morpholinos on the 
splicing pattern are indicated as well. Grey boxes represent the exons (numbers indicated) and 
black lines connecting the boxes represent the introns. C. Agarose gel showing products of RT-
PCR analysis of RNA samples from 31hpf embryos injected with either MO1 (panel 1 and 2) or 
MO2 (panel 3 and 4). Panel 1 shows a 360bp product after using primers fw1 and rev1. Increased 
production of this band was shown in MO1-injected samples. Panel 2 shows a 400bp product after 
using primers fw2 and rev2. The MO1-injected sample shows a decreased production of this 
amplicon. Panel 3 shows a 789bp product after amplification using primers fw3 and rev3. The 
MO2-injected sample shows an increased production of this amplicon. Panel 4 shows a 361bp 
product using primers fw4 and rev4. The MO2-injected sample shows a decreased generation of 
this PCR product compared to control.
Zebrafish embryos at the 1-2 cell stage were injected with 0.05pmol of MO1 and 
no obvious morphological changes were observed in 1 day old injected embryos (data not 
shown). At 31h post fertilization (hpf) the effect of the morpholino injection on the 
splicing of the zGR pre-mRNA was analyzed by RT-PCR (Fig. 1C, panels 1 and 2). Two 
primer pairs were used: pair 1 *:BD
'H'82a
sequence unique to the & 
	
)    results in a 400bp amplicon 
corresponding to the region between exon 7 and exon 9 (a sequence unique to the zGR	
transcript). Using pair 1, an increased production of the 360bp PCR amplicon was 
observed in MO1-injected samples compared to controls, reflecting a MO1-induced shift 




analysis using pair 2 showed a decreased production of the 400bp amplicon in MO1-
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Quantitative PCR (qPCR) analysis of RNA samples from 31hpf MO1-injected embryos 




variant compared to standard control morpholino (SC-MO)-injected embryos and a 
substantial decrease (approximately 15-
(
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for 6h and total RNA samples were collected for qPCR analysis. For all genes analyzed with 
qPCR, specific primers were used (sequences shown in Suppl. Table 4). The relative mRNA 
concentrations were normalized to those of Bactin1 and the values shown are the means ± s.e.m. of 













injections whereas no significant difference between SC-F@&*&3$>	
*
was detected. Dex did not a	
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concentration compared to SC samples. No effect on 
'
&-isoform due to 
dex treatment was detected. Asterisks (*) correspond to a statistical significance of p <0.001 
compared to SC-MO injected groups.  
In order to downregulate the expression levels  
 &  &, we 
designed a splice-blocking morpholino against the splice donor site of exon 2 of the zGR 









is truncated at amino 
acid 367, due to the introduction of a translational stop codon, which is encoded by 
nucleotides 2-4 of intron 2. This truncated GR lacks the DNA-binding domain (amino 
acids 394-454) and the C-terminal ligand-binding domain so it can be considered inactive. 
Zebrafish embryos were injected at the 1-2 cell stage with 0.05pmol MO2 and no obvious 
morphological changes were observed in 1 day old injected embryos (data not shown). At 
31hpf, the effect of MO2 injection on the splicing of the zGR pre-mRNA was analyzed by
RT-PCR (Fig. 2D and E). Two primer pairs were used: pair 3 amplifies a 798 base pair 
(bp) region between the 5’ end of exon 2 and the 3’ end of the adjacent intron 2, whereas 
pair 4 results in a 361bp amplicon corresponding to the 5’ end of exon 2 and the 3’ end of 




product in MO2-injected samples compared to controls, reflecting increased retention of 
the intron 2 sequence due to an effective block of the splice donor site of exon 2 by MO2
(Fig. 1C, panel 3). Pair 4 showed an increased amplification of the 361bp product in MO2
injected samples compared to controls, also reflecting increased intron 2 retention (Fig. 
1C, panel 4). Analysis of MO2-injected embryos showed a significant downregulation of 
the expression of the transcripts of both zGR  & compared to SC-MO injected 
embryos, probably reflecting a decreased stability of zGR mRNA that contains the intron 2 
sequence (Fig. 2A and B). Together, these results show that MO2-mediated inhibition of 
the splice donor site of exon 2 is effective and leads to 

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&








zGR mRNA vehicle 7
dex 8
I. Clusters of zGR-regulated genes
A. Dex-regulated genes (138)
[1 vs 2]
B. Dex-regulated and zGR-dependent (78)
[1 vs 2] overlap with [2 vs 4] & [2 vs 6]
C. zGR-dependent in absence of dex (81)
[1 vs 3] overlap with [1 vs 5]
II. Clusters of zGR-regulated genes
A. zGR-dependent (7)
[1 vs 7] overlap with [1 vs 5]
B. zGR-dependent, high expression (393)
[1 vs 5] not in [1 vs 3] & [1 vs 7]
C. Dominant-negative regulation by zGR (4)
[1 vs 2] overlap with [2 vs 8]
Figure 3. @++  
 *	( 
  &-  &-mediated effects on 
transcription, analyzed using Rosetta Resolver 7.2 software. The left panel indicates the eight 
different treatment groups, and the right panels each indicate three clusters of either zGR	- (top 
panel) or zGR-regulated (bottom panel) genes. For details on the different comparisons, see text. 
The number of genes (shown in parentheses) refers to annotated genes found to be significantly 
regulated at a p-value cutoff of <10-10 and fold changes either >2 or <-2. Annotation and probe 
assignment was performed based on the Ensemble Gene ID codes (ENSDARG).
Experimental design of the microarray experiment 
We used 1 day old zebrafish embryos and performed a whole transcriptome analysis in 
order to study the GR signaling pathway upon altering of the expression levels of both the 
&   -isoforms and treatment with the synthetic GC dexamethasone (dex).
Zebrafish embryos at the 1-2 cell stage were injected with either 0.05pmol SC-MO






2), and 0.05pmol SC-MO was co-injected in this group for proper comparisons to the other 
groups. The next day injected embryos were treated with either dex or vehicle for 6h. 
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Thus, 8 groups were generated: SC-MO/vehicle, SC-MO/dex, MO1/vehicle, MO1/dex, 
F@J+	) F@J') & *&3$J+	)  & *&3$J', .
 
analyzed using the Rosetta Resolver 7.2 software, setting signatures for significantly 
regulated probes at a p-value cutoff of p<10-10 and fold changes either >2 or <-2. An 
overview of all treatment groups and a summary of the results are presented in Fig. 3. 
Microarray analysis of zGR-mediated gene transcription  
First, the regulation of gene transcription due to dex treatment was studied, and for this 
purpose the SC-MO/veh and SC-MO/dex groups were compared. We identified 479 
probes to be significantly regulated and these were attributed to 138 annotated genes, of 
which 128 were found to be up-regulated and only 10 to be down-regulated upon dex 
treatment. By means of qPCR, the induction of 4 genes (rhcgb, agtxb, hsd11b2, and
slc5a1) found in our microarray analysis to be dex-upregulated (with at least two probes 
showing this effect) was validated and verified (Fig. 4). Using the PathVisio software for 
attributing gene ontology to the cluster of significantly regulated probes, specific 
molecular pathways were revealed to be influenced by dex treatment. Of these, the 10 
pathways with the highest Z-scores are listed in Suppl. Table 1, and an enrichment of 


















slc5a1 rhcgb agtxb hsd11b2
*
Figure 4. Validation by qPCR of gene regulation by dex identified by microarray analysis. 
Zebra *(    

 
 DDEF '  B 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* 
processed for qPCR analysis. For all genes shown, the mRNA concentration was significantly 
higher in the dex-treated group compared to the vehicle group. These data provide confirmation of 
our microarray analysis for dex-mediated gene transcription. Validation of microarray results by 
qPCR was performed on the same RNA samples as those used for microarray. Asterisks (*) 
correspond to a statistical significance of p <0.005. 
In order to study whether gene regulation by dex is dependent on the zGR
expression level we compared this cluster of dex-regulated genes with those found to be 
significantly changed due to MO1 and MO
 in the presence of dex (comparison SC-
MO/dex vs. MO1/dex and SC-MO/dex vs. MO
/dex respectively). A number of 78 genes 
were identified to be present in all 3 clusters (Fig. 5), which means that the observed 
regulation by dex is dependent on the presence of zGR. Of these genes, 71 were dex-
induced and 7 were suppressed upon dex treatment, and all genes verified by qPCR to be 
dex-regulated (slc5a1, rhcgb, agtxb and hsd11b2 (Fig. 4)) were present. These 78 genes 
account for 57% of the genes in the dex-regulated cluster, indicating that the majority of 
dex-regulation observed in our microarray is significantly compromised upon morpholino 
knockdown of zGR(it must be noted that effects of MO can also result from an 
upregulation of zGR expression, and this point will be discussed below). This result 
chapter 3
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demonstrates the validity of our experimental approach and provides a corroborated set of










dex-regulated and zGR-dependent genes
49994442078751
Figure 5. Venn diagrams showing the identification of the cluster of dex-
  &-
dependent genes. First, the overlap between genes regulated by dex (SC-MO/vehicle vs SC-
MO/dex, white circle) and genes regulated by MO2 in the presence of dex (SC-MO/dex vs 
MO2/dex comparison, grey circle) was determined (87 genes). Subsequently, the overlap between 
genes regulated by dex (SC-MO/vehicle vs SC-MO/dex, white circle) and genes regulated by MO1 
in the presence of dex (SC-MO/dex vs MO1/dex comparison, grey circle) was determined (94 
genes). The overlap between these two clusters was determined, yielding the cluster of dex-
regulated and zGR-dependent genes (78 genes).
Subsequently, we studied the 	
&' in the absence of dex on 
gene transcription regulation by comparing the SC-MO/veh and MO2/veh groups, and this 
analysis showed that MO2 injection significantly affected 604 probes which represented 
185 annotated genes, 133 of which are upregulated and the rest 52 are downregulated (Fig 
B, !  
 ( 
 &-specific target genes more stringently, we identified 
probes which were regulated by MOas well, since this morpholino decreases the 
expression of zGR too (in addition to increasing the zGR expression). We identified 
1401 probes to be significantly regulated as a result of MO1 injection, and they were 
attributed to 482 annotated genes, 321 of which are upregulated and the rest 161 are 
downregulated. A number of 81 genes were regulated by both MO1 and MO2 (Fig. 6). 
This cluster of genes regulated by both MOs accounts for 44% of the MO2-affected genes 
and 17% of MO1-affected genes. Validation by qPCR was performed for 4 of these genes 
and all of them were shown to be significantly upregulated due to both morpholinos in this 
experiment (Fig. 7). Further analysis using the PathVisio software for attributing gene 




distinguished the p53 pathway with 8 of its components to be regulated (and 2 of them 
(tp53 and casp8) to have been verified as z&-regulated genes by qPCR (Fig. 7)). This 
	
	&-dependent, and surprisingly it is completely distinct 
from the dex-dependent cluster we described in the previous section, since there is no 
overlap at all between these clusters. This indicates that in the absence of dex a different 
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set of genes is regulated by zGR than upon dex treatment, suggesting that zGR acts 
upon a different set of genes when activated by basal GC levels (presence of endogenous 










Figure 6. Venn diagram showing the identification of clusters of genes that are zGR and -
dependent. The left (light grey) circle contains the cluster of genes found to be significantly 
regulated by MO2 injection in the absence of dex (SC-MO/vehicle vs MO2/vehicle comparison). 
The middle (white) circle contains the genes found to be significantly regulated by MO1 injection 
in the absence of dex (SC-MO/vehicle vs MO1/vehicle). The overlapping region between these 
two circles contains the cluster of 81 gene regulated upon MO1 and MO2 injection (in the absence 
of dex),)	&-dependent. The right (dark grey) circle encompasses 
the genes found to be regulated upon GR mRNA injection (SC-F@J+	 + &
mRNA/vehicle). The overlap between the right and middle circle contains the 7 genes which are 

 ( 
 & *&3$  F@ >	
  
 	  ',   
	&-dependent. The 394 genes which are exclusively regulated by MO1 we consider 
as regulated by zGR)
/&+'+
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Figure 7. Validation by qPCR of MO-regulated genes identified by microarray analysis. The 
transcription rates of all genes examined were significantly higher in both MO1- and MO2-injected 
groups compared to the SC-MO group. These data provide confirmation of the results from our 
microarray analysis for 
  2&-dependent transcription in the absence of dex).
Asterisks (*) correspond to a statistical significance of p <0.005. 
. 
Microarray analysis of zGR-mediated gene transcription  








expression levels of both isoforms are affected, we cannot attribute any specific gene 












&*&3$lted in 353 significantly regulated 







 & *&3$-regulated cluster with the MO1-regulated cluster. This 
( + 

 ( H   	
 ( 
 >	
  F@  &
*&3$24,B,*		
 K;L 
&*&3$-affected genes and 




   * 
 &*&3$-regulated cluster and none of the observed 
effects could be verified (Suppl. Fig. 1). The low level of overlap between MO1-affected 
&*&3$-affected genes and the failure to validate the observed regulation 
of several genes by qPCR makes the relevance of this small cluster of supposedly zGR-
regulated genes questionable.
When we compared MO1-regulated genes to MO2-  & *&3$-regulated 
ones, we identified a pool of uniquely MO1-affected genes (Fig. 6). We found 1035 probes 
that were uniquely regulated and they were attributed to 394 annotated genes. Validation 
by qPCR was performed on 5 of these genes and 2 of them showed to be significantly 
regulated by MO1 (Fig. 8). Further analysis of this cluster of uniquely MO1-regulated 
genes by using the PathVisio software for attributing gene ontology to regulated probes 
revealed particular pathways to be specifically affected due to shifting splicing towards 
	 & 	
 2=,  :,   	
 	  ' 
evidence for an intrinsic transcriptional activity of zGR(although regulation in this case 
( /  & ' + 
 
 +s observed u &
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Figure 8. Validation by qPCR of unique MO1-regulated genes identified by microarray analysis. 
The mRNA concentration levels of cyp2( ) and LOC794635 were significantly higher only in 
MO1 injected group compared to SC one. The rest of the genes tested did not show any differential 
regulation. Asterisks (*) correspond to a statistical significance of p <0.01. 
Finally, in order to examine a possible dominant-negative effect of &) 
studied whether dex-induced regulation of gene transcription was affected by an altered 
expression level of zGR Therefore, we considered the cluster of dex-regulated genes and 
compared it with the cluster of zGR mRNA-regulated genes in the presence of dex
(comparison SC-MO/dex vs &*&3$J'). The overlap between these clusters, being 
the cluster of genes of which transcriptional regulation upon dex treatment was 
significantly compr*
&mRNA-injected group, consisted of only 4 genes,
which constitutes <3% of the dex-affected gene cluster (Fig. 9). Further validation by 
qPCR on 3 of these genes (expression of il17a/f2 gene was not detectable by qPCR)
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showed that only the expression of si:ch211-234p6.12 was significantly aff	
(&
mRNA injections whereas for the other two genes tested (si:ch211-284e13.2 and zgc: 
163121), no such effect was observed (Fig. 10). Thus, our analysis shows that only a very 






Figure 9. Venn diagram showing the analysis of the possible dominant-
+	+
(&,
The white circle contains dex-regulated genes (SC-MO/vehicle vs SC-MO/dex) and the grey circle 
	* 
&*&3$-regulated genes (SC-F@J'+&*&3$J',+


























































































Figure 10. Validation by qPCR of the dominant-negative effect of zGR. A. The dex-mediated 
upregulation of si:ch211-234p6.12   	
( 	**  
 & *&3$





 & *&3$ >	
 	* 
=-MO 
injected group. C. The dex-mediated downregulation of zgc: 163121 gene was not significantly 

  







-negative effect only on the si:ch211-234p6.12 gene. 
Asterisk (*) indicates a statistical significance of p <0.001. 
Discussion
Recently, the zebrafish embryo model has emerged as a potent in vivo system for gene 
knockdown studies using morpholinos. These agents efficiently block either the translation 
of expressed transcripts or their proper splicing, thus enabling functional characterization 
of gene activity at the whole organism level [45, 49]. In the present study, we have 











-isoform under basal conditions as well as after dex treatment. For this purpose, two 
different (splice-blocking) morpholinos were used. One that directs alternative splicing of 
the zGR pre-*&3$ 




		&-isoform (MO1), and another that functionally knocks 
down both the zGR - and -*2F@, !
)&*&3$>	

used to specifically increase zGR expression. The efficacy of the morpholino treatments 
was tested by PCR, showing that the splice pattern was altered as expected. 
Neither the morpholino trea
*
  >	
  & *&3$ 	 (
obvious morphological abnormalities during embryonic development. This observation is 
consistent with other studies, in which different splice-blocking morpholinos were used for 
a functional knockdown of zGR [50, 51]. In mice, knockout of GR has been shown to be 
lethal several hours after birth, mainly as a result of compromised lung development [52].
This apparent paradox could be due to the fact that our splice-blocking morpholino 
treatment does not result in a complete knockout and does not affect maternally deposited 
mRNAs (so morpholinos start to act after the onset of zygotic transcription (~4-5hpf). 
Alternatively, zebrafish development may be more resistant to fluctuations in GR 




  &  &
transcripts led to significant transcriptional changes as shown by microarray analysis and 
further qPCR validation.








this purpose, we compared the control (SC-MO)-injected group treated with vehicle with 
the control-injected group treated with dex, and we identified 138 genes that were 
significantly regulated upon dex treatment. From these genes, 4 (slc5a1, agxtb, rhcgb and
hsd11b2) were tested by qPCR and the regulation observed in the microarray was verified 
for all 4 (Fig. 4). Moreover, gene ontology analysis (Suppl. Table 1) showed that 
metabolic pathways (e.g. cytochrome P450-dependent metabolism, citrate cycle, 
glutathione metabolism, steroid hormone biosynthesis) are particularly induced upon dex 
treatment, alongside other pathways well-known to be affected by GC signaling like the 
insulin [53] and prostaglandin signaling pathway [54]. Our dex-responsive gene set, 
obtained in an in vivo model, could complement data derived from previous studies in 
which researchers also availed themselves of microarray technology in order to identify 
GR target genes and characterize their transcriptional regulation [55-58]. In some of these 
studies, gene ontology analysis also revealed GR activation to affect metabolic pathways 
as we found in our data set [59, 60].
Moreover, further examination showed that for the majority (57%, 78 genes) of 





rest of the dex-regulated genes could either be less sensitive to & +
( 2*

likely due to different promoter affinities for GR occupancy [61-63]) or represent false 
positive results. Thus, this analysis provided us with a corroborated set of 78 genes which 
 
  ' 

*
   	 
 
  &-dependent. In 
addition, it confirmed the validity of our microarray experiment.
3'
)'*	
		&5	5 (Fig. 6) by 
both MO1 and MO2 (in the absence of dex). We identified 81 genes to be significantly 

 




dependency was verified for all 4 of them (Fig. 7). Gene ontology analysis unveiled 
specific p
( 
  	 ( & under basal conditions. These pathways 
65
 
concern (among others) apoptosis, the Androgen receptor signaling, the MAPK signaling, 
and the cell cycle (Suppl. Table 2). From this list, we distinguished the p53 pathway with 7 
of its components 
  	 2  
    
 5	5  &,




 p53 pathway and 
this finding is in line with the results of many other studies, both in zebrafish and in other 
systems. In a microarray study by Pikulkaew et al. [51], the use of a morpholino targeted 
against the zebrafish GR also led to a substantial induction of tp53 and casp8 at 10hpf 
[51]. Another interesting observation comes from a study by Danilova et al. [64], who 
showed that long-term (1-3 days) dex treatment suppressed tp53 levels that were initially 
elevated due to rpl11 gene mutation. In mammalian systems, GR and p53 can physically 
interact and impair each other’s transcriptional activities (e.g. via sequestration in the 
cytoplasm [65-67]) as well as act synergistically [68-70]. Additionally, there are data on a 
negative correlation between p53 and GR levels [71, 72]. Since most of this research has 
been done using cell lines, the zebrafish could provide a powerful in vivo model in order to 
elucidate the molecular mechanism of interaction between GR and p53 and explore the 
biological outcome at the whole organism level, e.g. alterations in the level of apoptotic 
cell death during development.  














different set of target genes under basal conditions than upon activation by dex. Upon dex 
treatment various metabolic pathways are induced, whereas morpholino knockdown of the 
receptor activates immune-releated pathways and the MAPK signaling cascade (Suppl. 
Tables 1 and 2). These findings put forward the idea of two distinct gene sets; one set to be 
regulated under basal conditions for maintenance of homeostasis (e.g. in our case by 
suppressing p53 pathway) and the other to be regulated upon a stressful stimulus in order 












target genes, which may be for example due to different binding affinities for ligand-bound 
	
  
 &<, 6	) *  	 (  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  &








5[61-63]. In support of 
this notion, a recent study by Reddy et al. [73] showed variation in the sensitivity of genes 
to siRNA treatment against the GR. Further examination of the GRE architecture of genes 
















in order to reveal a possible intrinsic transcriptional activity of this isoform. Therefore, we 
investigated whether there was any overlap between the cluster of MO1- and zGR
mRNA-affected genes (in the absence of dex). This analysis resulted in a cluster of only 7 
 
  
 & overexpression by both MO1 and zGR mRNA (Fig. 6). 
M
 ( /%&    
   
 +( 
 &-mediated regulation
observed in the microarray. This failure to verify the regulation in combination with the 







this cluster represents false positive hits. 
A surprisingly large cluster of 394 genes was identified that was regulated 




they are not regulated by zGR but exclusively by zGR, whereas the lack of regulation 
upon zGR mRNA injection suggests that regulation of these genes requires relatively 
 & +) 	 /%& (  
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by qPCR confirmed the induction of 2 genes, Cyp24a1 and LOC794635 (out of 5 genes 
tested, Fig. 9), which are involved in Vitamin D3 metabolism and the immune response 
respectively [74, 75]. Applying gene ontology analysis to this cluster of uniquely MO1-
regulated probes revealed specific signaling cascades to be regulated like that of TGF-beta, 
delta-notch, Id, noncanonical wnt, and pentose phosphate as well as fructose and mannose 
metabolism (Suppl. Table 3). This gene cluster could reflect specific target genes for 
&) 
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only 4 genes for which the dex-induced gene transcription was significantly compromised 
 
 &*&3$ >	
) accounting for <3% of the cluster of dex-affected genes. 
Validation by qPCR of these 4 genes confirmed a dominant-negative effect on 1 of those 








Nevertheless, we cannot rule out that very specific and limited effects (as in the case of 
si:ch211-234p6.12) can be attributed to a dominant-
+ 	
  &, N

respect to this notion, in mice it was shown that GR's dominant-negative activity was 
specific for a subset of genes, but still 4 out of 6 genes tested showed a dominant-negative 
effect, suggesting a much lower level of specificity than observed in our study for zGR
[31]. Alternatively, the dominant-negative activity of zGR may require higher expression 











profound effect for this receptor, but suggest particular requirements such as high 
' +   		




conclusion is in line with controversial data obtained from overexpression studies of the 
* &) 	 + 	
	 	oncerning its inhibitory effects among 






In summary, our microarray analysis of the zGR signaling in 1dpf zebrafish 
embryos identified two distinct zG&-dependent gene clusters. One that is affected at 
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Supplemental Figure 1. M	
 ( /%&  & *&3$  F@-mediated intrinsic 
transcriptional activity on LOC564200, cab39 and uox identified by microarray analysis. Groups 






Pathway Genes meeting criteria Z scores
Drug metabolism - cytochrome P450 3 5.6
Metabolism of xenobiotics by cytochrome P450 3 5.37
Prostaglandin signaling 3 4.97
Glutathione metabolism 3 4.79
NOD pathway 3 3.71
Insulin signaling pathway 5 3.51
Toll like receptor pathway 5 3.47
Adipocytokine signaling pathway 3 3.4
Citrate cycle (TCA cycle) 2 3.26
Steroid hormone biosynthesis 2 3.07
Supplemental Table 1: Molecular pathways revealed by PathVisio gene ontology analysis of 
dex-regulated genes. 
Pathway Genes meeting criteria Z scores
p53 signaling pathway 8 10.83
G1 to S cell cycle control 4 6.13
Androgen Receptor Signaling Pathway 4 4.38
MAPK signaling pathway 4 3.26
RIG-I-like receptor signaling pathway 3 3.19
Apoptosis 3 3.12
Cell cycle 4 3.08
Glycosaminoglycan biosynthesis - chondroitin 
sulfa 1 2.93
NOD-like receptor signaling pathway 2 2.72
Toll-like receptor signaling pathway 3 2.7
Supplemental Table 2: Molecular pathways revealed by PathVisio gene ontology analysis for 




Pathway Genes meeting criteria Z scores
TGF-beta 9 4.92
Id Signaling Pathway 4 3.61
Toll like receptor pathway 8 3.45
noncanonical wnt pathway 7 3.2
Nodal signaling pathway 5 3.14
neural crest development 4 2.96
Fructose and mannose metabolism 3 2.64
Pentose Phosphate Pathway 1 2.64
Delta-Notch Signaling Pathway 4 2.59
IFN Pathway 6 2.57
Supplemental Table 3: Molecular pathways revealed by PathVisio gene ontology analysis for 
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In humans, two splice variants of the glucocorticoid receptor (GR) exist: the canonical 
human & -isoform 2&, acting as a ligand-activated transcription factor, and the 
human &-isoform 2&, which has been shown to have a dominant-negative effect 
on h&, Several studies have shown that elevated h& + are associated with 
resistance to anti-inflammatory glucocorticoid treatment. In the present study we have 
used the zebrafish model system in order to elucidate the functional role of the GR -











 & * 2&, 6+)  	 ct was 
observed in zebrafish PAC2 cells using induction of the fkbp5 gene as readout. In addition,
& mRNA injections in 1-2 cell stage zebrafish embryos, no effect was observed 

&-induced transactivation of the fkbp5, pepck and +  genes. Subsequently,
we generated a transgenic fish line with inducible & +'ion. Transcriptome 
analysis by microarray and subsequent qPCR validation using this line did not reveal any 

( 	
  & (either as a dominant-negative inhibi





  &. Based on these results, we suggest that the 
zebrafish GR -isoform does not have a regulatory role in transcription and that splicing of 
the GR pre-mRNA into a messenger encoding an alternative splice variant could instead 
represent a physiological mechanism to downregulate the levels of the canonical receptor 
variant
Introduction
The glucocorticoid receptor (GR) is expressed almost ubiquitously in the human body and 
regulates a wide range of biological processes such as our metabolism, growth, 
reproduction, vascular tone, bone formation, immune response and brain function [1-6]. 
The GR is activated by binding of its cognate ligands (glucocorticoids (GCs)), and upon 
activation it acts as a transcription factor. In its inactive state, the GR mainly resides within 
the cytoplasm in a multiprotein complex containing chaperones and immunophilins. Upon 
glucocorticoid binding, the GR is released from its cytoplasmic complex and translocates 
to the nucleus, where it orchestrates gene expression via DNA-binding dependent and 
independent mechanisms. DNA-binding dependent mechanisms involve GR binding to 
glucocorticoid response elements (GREs), where it recruits transcriptional coregulators 
and thus, directs (positively or negatively) the transcription rate of target genes. The mode 
of GR action by which DNA binding leads to upregulation of gene expression is known as
transactivation. Independent of DNA-binding, the GR can also physically interact with 
other transcription factors (e.g. NF-"#$%-1), via which it can either synergistically 
induce gene expression or repress activation of genes. The latter mode of action is called 
transrepression and comprises one of the classical ways by which GCs exert their anti-
inflammatory effects [1, 2, 7-11].  






within the last coding exon (exon 9) [12, 13]. The two isoforms are identical between 
amino acids 1 and 727, thus sharing the same N-terminal domain and DNA binding 




(LBD),&-isoform (777 amino acids) is able to interact with GCs, and represents 

		 	
,&-isoform (742 amino acids) has a shorter LBD with a 
unique C-terminal 15 amino acid sequence, which renders it unable to respond to GCs [12-
14].
Almost ten years after the discovery of hGR, it was shown (using in vitro reporter 
assays) that this isoform had a pronounced dominant-negative inhibitory 	
&0
transactivational properties [15-17],F+)&-mediated transrepression of in vitro
reporter assays was also reported to be inhibited by &[17]. These findings were soon 
coupled to clinical data demonstrating a positive correlation between high expression 
+  
 -isoform and GC resistance of patients suffering from immune-related 
disorders, like asthma [18-23], ulcerative colitis [24-26], leukemia [27-29] and rheumatoid 
arthritis [30, 31]. Further cell-based research supports an inhibitory role for hGR on both 
&-induced transactivation and transrepression of endogenous genes (MKP-1, 
*(	) 	
) 34  !-B [23, 32, 33]), as    &-mediated 













@+'& has been demonstrated to attenuate NF-"#$%-1 induction of 
luciferase reporter constructs [37], as well as GATA3-mediated activation of IL5 and IL13 
promoters of luciferase genes [38]. Additionally, transcriptome analyses of cultured cells 
 
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 & -isoform, its physiological relevance has often been 
questioned. First, in many studies the dominant-
+   &  &0
transcriptional properties could not be demonstrated in in vitro reporter assays [37, 38, 41-
46]. Second, despite the fact that hGR is expressed in almost all human tissues, its 
' +  	
(  	* 
 & [15, 16, 34, 47-49].  This
raises doubts about its in vitro dominant negative effect, since in most studies this required 












expression of this isoform was only found in humans, and that rodents contained a 
mutation in the splice site required for GR expression [50]. It was therefore remarkable 
that we discovered the occurrence of a GR -isoform in zebrafish [51]. Like humans, 






-isoforms share the same N-terminal domain and DBD and only differ at the C-terminus 





specific sequence is found in exon 9, in the zebrafish it is located in exon 8. Usage of the 
most 5’ splice donor site in this exon results in a shorter version of exon 8 and an mRNA 
	 &, 9  
 *




exon 8 that introduces a stop codon within that exon, resulting in an mRNA encoding 
& [51], ) 




-specific sequences, but they share 
the same point of divergence at the protein level [51, 52]. Interestingly, an alternative 
	 +





 '   & -isoform in 
zebrafish was recently discovered in mice [53].
Both the *   & -isoforms exhibit the same predominantly 





mediated transactivation in in vitro reporter assays [51]. -5
*/+
)&
is ubiquitously expressed, and at significantly l + 	* 
 & [51]. All 
these data point to convergent evolution of hGR and zGR, which most likely emerged 
due to a common biological need for regulation of specific signaling pathways [51]. 





contributor to biomedical research for an array of human diseases [54, 55]. It is easily 
handled and maintained and produces big clutches of embryos, which are fertilized 
externally and develop rapidly [56]. Moreover, its genome has been sequenced and 
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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zed both in vitro and in vivo approaches. For the in 
vitro studies, we performed luciferase assays in COS-1 cells transiently transfected with 
&, $
()   
  %$ 	 )  	  + 
(
+'&
the transcription rate of several endogenous target genes. 
For in vivo '*
)++'&(**&3$>	
 
*()  + 
  
	   
  	 &
expression construct. While a clear dominant-
+ 	
  &  + 





the expression of endogenous genes. Therefore, our study does not support the proposed 
functions of the GR -isoform as a dom
 
+ 
  & or as a
transcription factor 














COS-1 cells (African green monkey kidney cells were cultured in DMEM (Invitrogen), 
supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin and 
streptomycin (Invitrogen). Cells were grown at 37C and 5% CO2. PAC2 zebrafish cells
were cultured in Leibovitz’s medium (Invitrogen), supplemented with 15% fetal bovine 
serum (Invitrogen) and 1% penicillin and streptomycin (Invitrogen). Cells were grown at 
28C.
Luciferase reporter assays in COS-1 cells 
COS-1 cells were seeded into 24-well plates (3x104 
51
cells/well). Transfection was 
performed 24h later using the TransIT®-COS Transfection Kit (Mirus Bio) according to 
the manufacturer’s instructions. For the experiments in which the transactivation activity 
of zGR	 was assayed, 200ng MMTV-luciferase reporter construct was transfected, with a 
  %=P& * 		

 2-300ng) and/or 100ng pCS2P&
expression vector (previously described in [ ]), together with 2ng CMV-renilla 
(Promega). For the experiments in which the transrepression activity was assayed, cells 
were transfected with ;D    "#-luciferase reporter construct (	
 ; "#
response elements (Stratagene)) and 50ng of a human p65 expression vector (pCMV4-p65,
described in [58]), together with a range of pCS2P& concentrations (0-1000ng) in the 




always kept equal among groups by transfecting empty pCS2+ vector. Twenty-four hours
after transfection, cells were treated with 100nM dexamethasone (Sigma) and 24h later,
they were assayed for luciferase activity using the Dual-Luciferase® Reporter Assay 
System (Promega). Bioluminescence was detected using a Wallac 1450 MicroBeta 
Luminometer. For each sample, the luciferase activity was normalized to the renilla 
activity. Per sample, measurements were performed in duplicate, and data shown are 
averages ± s.e.m. of three individual experiments. 
Generation of the PAC2-
For the generation of a 
	+'&)the pCS2P&*[51]
and a neomycine resistance plasmid were transfected into PAC2 zebrafish cells using the 
Amaxa® Cell line Nucleofector kit V and the Nucleofector™ II device set at T27 
programme (Lonza). Four days after transfection, cells were subjected to selection for 
antibiotic resistance by supplementing their culture medium with ;DDEg/ml of geneticin 
(G418, Invitrogen). Resistant cells were propagated to establish the PAC2-&	,
Glucocorticoid treatment of PAC2 cells for gene expression analysis 






 DEM betamethasone 17-valerate (Sigma) or vehicle (<2% 
DMSO) in complete culture medium for 3h. Samples were collected in TRIzol® reagent 
(Invitrogen) and total RNA was isolated following the supplier’s manual (Invitrogen).
RNA isolation & cDNA synthesis 
Total RNA was extracted using the TRIzol® reagent (Invitrogen) according to the 
manufacturer’s instructions (Invitrogen). RNA was dissolved in water and denatured for 5 
min at 60C. Samples were treated with DNAase using the DNA-free™ kit (Ambion). For 
microarray analysis, RNA was further purified using the RNeasy MinEluteTM Cleanup kit 
from Qiagen and its integrity was checked with a lab-on-chip analysis using the 2100 
Bioanalyzer (Agilent Technologies). For subsequent cDNA synthesis, at least 200ng of 
total RNA was added as a template for reverse transcription using the iSCRIPTTM cDNA 
Synthesis Kit (Biorad). Non reverse-transcribed samples were also generated to be used as 
negative controls during the quantitative polymerase chain reaction step.
Quantitative Polymerase Chain Reaction (qPCR) 
qPCR analysis was performed using the MyiQ Single-Color Real-Time PCR Detection 




cDNA) El forward and reverse primer (10EM) and 12.5El of 2x iQ™ SYBR® Green 
Supermix (Biorad). Cycling conditions were 95C for 3 min, followed by 40 cycles of 15 
sec at 95C, 30 sec at 60C and 30 sec at 72C. Ct values (cycle number at which a 
threshold value of the fluorescence intensity was reached) were determined for each 
sample. A dissociation protocol was added, determining dissociation of the PCR products 
from 65C to 95C, allowing discrimination of specific products. In order to determine the 
efficiency of the amplification reaction, serial dilutions of cDNA were used and standard 
curves were generated plotting the Ct values against the relative cDNA concentration. The 
linear slope of the standard curve for each primer pair was determined and the efficiency 




 . This was done for 
the target gene and a reference gene.  Finally, the Ct value was determined by subtracting 
the Ct value of the experimental sample from the Ct value of a control sample, and the fold 
79
 














arg . In all qPCR experiments, a non-reverse 
transcribed sample and a water-control were included. All cDNA samples were assayed in 
duplicate. Values shown are means ± s.e.m of three individual experiments. Sequences of 
all primers used for qPCR analysis are included in Suppl. Table 4. 
Zebrafish strains, husbandry & egg collection 
Wild type adult ABxTL zebrafish and the transgenic lines Tg(hsp70:Gal4) (provided by 
Dr. H. Baier, University of California, San Francisco, USA) and Tg(UAS:GFP-*&(see 
‘Generation of the Tg(UAS:GFP-*& transgenic line’ later in this section) were used in 
this study. Livestock was maintained and handled according to the guidelines from 
http://zfin.org. Fertilization was performed by natural spawning (single crossings) at the 
beginning of the light period and eggs were raised at 28C in E3 egg water medium 
	
 BDEg/ml Instant Ocean sea salts supplemented with 0.0025% methylene blue 
(GURR). All experimental procedures were conducted in compliance with the directives of 




pCS2+& *   








from Ambion. Newly synthesized mRNA was purified using the RNeasy MinEluteTM





60C for 5min and 
diluted at a final concentration of 5ng/El in 1x Danieu’s buffer (58mM NaCl, 0.7mM KCl,








Glucocorticoid treatment of 	embryos 
Twenty-eight hours post fertilization embryos injected with & *&3$ were 
dechorionated and placed in 2% agarose-coated Petri dishes, where they were incubated 
with 100EM dexamethasone (Sigma) in E3 medium for 6h at 28C. Samples were collected 
in TRIzol® reagent (Invitrogen) and total RNA was isolated according to the 
manufacturer’s instructions (Invitrogen).
Generation of the UAS:GFP-


The &	sequence was amplified out of the p=P&*[51] using the 
CCCTCGAGCACCATGTACCCATACGATGTTCCAGATTATGCTATGGATCAAGG-
AGGCTGGA forward and CCGGATCCTCAGTTTGAAAACTGCCTTTGAA reverse 
primer. This primer pair also introduced the Xho and BamH1 restriction sites flanking the 




  6$ 
 
*  &, 
resulting amplicon was, then cloned into a pME-MCS vector ([59], provided by Dr. K. 
Kawakami (National Institute of Genetics, Japan). The HA-&-ME-MCS was further 
used as template for PCR amplification using the TCAGAATTCACCATGCTATGGATC-
AAGGAGGACTGG forward and CTAAAGGGAACAAAAGCTGGAGCTC reverse 
primer. The forward primer omitted the HA tag, while introducing an EcoRI site at the 5’ 




unique NotI restriction site at the 3’ end of the & sequence. The resulting amplicon 
was cloned into the 14xUAS E1b Tol2 transposon-based vector (provided by Dr. H. Baier,
University of California, San Francisco, USA). Furthermore, the destabilized green 
fluorescent protein (d1GFP) sequence was amplified from pd1EGFP-N1 vector (purchased 
from Clontech) using the TCAGAATTCATGGTGAGCAAGGGCGAGG forward and 
TCAGAATTCCGTTGTACAGCTCGTCCATGCC reverse primer, introducing EcoRI








of and in frame with the &	sequence.
Generation of the Tg(UAS:GFP-transgenic line
The plasmid pCS2FA-transposase (provided by Dr. K. Kawakami) was linearized with
NotI (New England Biolabs) and further used as a template for the mRNA synthesis using 
the mMESSAGE mMACHINE SP6 kit from Ambion [60]. Newly synthesized mRNA was
purified using the RNeasy MinEluteTM Cleanup kit from Qiagen and its integrity was 
checked on a 1.5% agaroze electrophoresis gel.
The UAS:GFP-& construct and the Tol2 transposase mRNA were diluted at a 
final concentration of 30 and 50ng/El respectively, in 1x Danieu’s buffer (58mM NaCl,
0.7mM KCl, 0.4mM MgSO4, 0.6mM Ca(NO3)2, 5mM HEPES at pH 7.6) containing 
0.05%  phenol red [60]. 1nl of mixed UAS:GFP-& DNA and transposase mRNA 
solution was microinjected at the single-cell stage eggs. Positive F0 founders were 
outcrossed again with wild type fish and their offspring were raised to adulthood. F1 adult 
fish were genotyped and positive F1 fish were subsequently used in crossings with the 
Tg(hsp70:Gal4) line [61].
Heat shock and glucocorticoid treatment of transgenic embryos
The Tg(hsp70:Gal4) and Tg(UAS:GFP-*&lines were crossed and their offspring were 
heat-shocked at 1dpf in Petri dishes filled with pre-warmed (37C) E3 egg water medium 
in a 37C incubator for 2.5h. The next day, embryos were screened for GFP expression 
and wild types as well as their GFP expressing siblings were subjected again to the heat 
shock protocol. Three day old hatched wild types and their GFP expressing siblings were 
checked again for GFP signal and treated with either vehicle (<2% DMSO) or 25EM
beclomethasone for 6h. Samples were collected in TRIzol® reagent (Invitrogen) for 
subsequent RNA isolation.
Microarray design
A 4x180k microarray chip platform (customized by Agilent Technologies, (Design 
ID:028233)) was used in this study. This array consists of all probes already present in an 
earlier 45.219 custom-made array [62], and another 126.632 newly designed zebrafish 
probes had been added as described in [63]. A total of 16 samples (4 experimental groups 
from 4 replicate experiments) were processed for transcriptome analysis. On each 4x180k 
slide, 4 samples from the different experimental groups within the same replicate were 
hybridized against a common reference.
Microarray amplification & labeling
Amplification and labeling of RNA was performed at the MicroArray Department (MAD) 
of the University of Amsterdam (Amsterdam, The Netherlands). Per sample, 0.5Eg total 
RNA was amplified and combined with Spike A according to the Agilent Two-Color 
Microarray-Based Gene Expression Analysis kit (Agilent technologies). As a common 
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reference sample an equimolar pool of all test samples was made and 0.5Eg samples were
amplified similarly as the test samples with the exception that Spike B was used. Amino-
allyl modified nucleotides were incorporated during the aRNA synthesis (2.5mM of each 
GTP, ATP, UTP (GE Healthcare), 0.75mM CTP (GE Healthcare), 0.3mM AA-CTP 
(TriLink Biotechnologies)). Synthesized aRNA was purified with the E.Z.N.A. MicroElute 
RNA Clean Up Kit (Omega Bio-Tek). The quality was inspected on the BioAnalyzer 
(Agilent Technologies) with the Agilent RNA 6000 kit (Agilent Technologies). Test 
samples were labeled with Cy3 and the reference sample was labeled with Cy5. 4+Eg of 
aRNA was dried out and dissolved in 50mM carbonate buffer pH 8.5. Individual vials of 
Cy3/Cy5 from the mono-reactive dye packs (GE He
	  +  DDE
DMSO. To each samp)DEl of the appropriate CyDye dissolved in DMSO was added 




4M hydroxylamine (Sigma-Aldrich). The labeled aRNA was purified with the E.Z.N.A. 
MicroElute RNA Clean Up Kit. Yields of aRNA and CyDye incorporation were measured 
on the NanoDrop ND-1000.
Microarray hybridization, scanning & data processing 
Each hybridization mixture was made up from 825ng Test (Cy3-labeled) and 825ng 
Reference (Cy5-labeled) material. Hybridization mixtures were using the Agilent Two-
Color Microarray-Based Gene Expression Analysis kit according to the manufacturer’s 
instructions (Agilent technologies). The samples were loaded onto the microarray chips 
and hybridized for 17h at 65C. Afterwards the slides were washed and scanned (20 bit, 
3μm resolution) in an ozone-free room with the Agilent G2505C scanner. Data was 
extracted with Feature Extraction (v10.7.3.1, Agilent Technologies) with the 
GE2_107_Sep09 protocol for two-color Agilent microarrays. The Agilent output from the 
16 hybridizations was then imported into the Rosetta Resolver 7.2 software (Rosetta 
Biosoftware, Seattle, Washington) and subjected to a factorial design with a re-ratio with 
common reference application. Data analysis was performed setting cutoff for the p-value 
of <10-5 and for fold change of either >2 or <-2. 
Statistical analysis
Statistical analyses (t-tests and two-way ANOVAs with Bonferroni post-hoc tests) were 

























 &   *
-negative 	
  &-mediated 
transrepression as well. For the studies on transactivation, COS-1 cells were transiently 
transfected with an MMTV-luciferase reporter construct and a range & expression 
vector amounts in the presence and absence of DD&*, Upon transfection, 
cells were incubated with 100nM dexamethasone (dex) for 24h and assayed for luciferase
activity. The results show that, as expected, the luciferase signal was increased upon 
	 		

  & 24, $, ! 
 	  &) 
 	
activity was strongly reduce) +  / *
  






























1 cells were transiently transfected with "#-luciferase construct, an expression vector for 
the human p65 subunit of the NF-"# 
	
 	
 	*'  &
expression vector amounts in th 	  	  DD & *, 9
transfection, cells were incubated with 100nM dex for 24h and assayed for luciferase 
activity. The results, shown in Fig. 1B, reveal that with 			

&)




(&. In these experiments)
	&id not affect 
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Figure 1. A. Dominant-
+ 	
+
(  &  
	
+
 ( ( 	
assays. COS-1 cells were transiently transfected with an MMTV-luciferase reporter construct and a
  & ' +	
 *
  	 2
   	 2(  
DD &)  	
 







means ± s.e.m. of three 
independent experiments. Statistical analysis by ANOVA revealed an effect of zGR expression 
(p=0.001). B. Lack of dominant-
+ 	
+
(  &  
 ( (
luciferase assays. COS-1 cells were transiently transfected with  "#-luciferase construct, an 
expression vector for the human p65 subunit of the NF-"# 
	
 	



















Transiently transfected reporter constructs contain simple promoters and are not embedded 
into chromatin structure.  In order to study the effect of zGR on endogenous promoters in 
vitro, we generated a PAC2 cell line that stably +'
&-isoform 
(PAC2-&. In PAC2-& cells, the zGR mRNA expression level was 260 fold 
higher than in wild type PAC2 cells (PAC2-wt)
'& was not 
different between these two cell lines (Fig. 2A and #, 
  &  







  & (Suppl. Fig. 1). Treatment with GCs did not 
significantly alter the expression of either splice variant (Fig. 2A and B). 
 &   
 






-17-valerate (BV) for 3h. Hence, we investigated the expression 
profile of a well-known endogenous GR-target gene, fkbp5 [64], by means of qPCR. Upon 
BV treatment, a more than 10-fold induction of fkbp5 was observed in both PAC2-wt and 
PAC2-&	)








transactivation of the fkbp5 gene in PAC2 cells. Several other known GR target genes 
(	*'	
, )''))-'
+'+  ) were tested for induction upon BV treatment 
in PAC2 cells. None of these genes showed increased mRNA expression upon treatment, 
leaving fkbp5  
 (  











































































Figure 2. A. =
 +'  
  & -isoform in PAC2 cells. Cells were 
stably transfected with a zGR expression vector for the generation of the PAC2-&,
&' + 
	ll line was determined by qPCR. The data show that the PAC2-
&	(+'2R;D



























 '  
 & -isoform due to either BV treatment or 
+'  







upregulate the expression of fkbp5 upon treatment with either DEF #M  +	  :,
Statistical analysis revealed that fkbp5 induction due to BV treatment does not differ between the 
two lines examined. In all figures mRNA expression measurements were normalized to those of 












 in vivo, we injected 1-2 cell stage 










  fkbp5, pepck and nfkbiaa. Dex treatment of control embryos 
resulted in approximately 100 (± 10.6 s.e.m.), 3.5 (± 0.9 s.e.m.) and 1.6 (± 0.25 s.e.m.) fold 
induction of fkbp5, pepck and nfkbiaa mRNA, respectively 24, :$) #  , &-
injected embryos treated with dex showed similar induction levels of these genes (Fig. 3A, 


















































































Figure 3. Expression levels of the GR target genes fkbp5 (A), pepck (B), and nfkbiaa (C) &
mRNA injected embryos, determined by qPCR. Embryos were injected at the 1-2 cell stage with 
; & *&3$, $







 DDEF '  B,
Expression levels were normalized to those of bactin1 and the relative mRNA concentration values 
shown are the means ± s.e.m. of three independent experiments. Statistical analysis by ANOVA 










&-induced transactivation of any of the genes tested in 1 day post fertilization zebrafish 
embryos.
Characterization of a Tg(UAS:GFP-
ne
Subsequently a fish line was generated which stably overexpressed &)  

Gal4/UAS expression system. We generated a Tg(UAS:GFP-*& line, in which the GR 
-isoform is fused to a green fluorescent protein (GFP) at its N-terminus and is 
downstream of a 14xUAS promoter that responds to the Gal4 transcription factor. This line 
was crossed with the Tg(hsp70:Gal4) line (in which Gal4 expression is controlled by a 
heat shock-inducible promoter), yielding embryos in which the zGR expression was 
induced upon a heat shock. Embryos at 1 and 2 day post fertilization (dpf) were heat 
shocked and the GFP signal was readily detectable within a few hours, reflecting 
expression of the GFP-
 & -isoform. Expression was clearly present in the 
muscles, yolk and eyes of 3dpf larvae (Fig. 4B). Further magnification suggested that 
GFP-&  	  
	 
	 24,)		*(	-
staining with Sytox Orange (data not shown). This observation is in line with previous data 
showing that a YFP-
 & '  @=-1 cells resulted in a more nuclear 
localization compared to YFP-&
*	
([51].
In order to confirm that the fusion protein was properly expressed, we performed a 
western blot analysis on samples from fluorescent and non-fluorescent embryos using an 
anti-GFP antibody. We could identify a specific band at the expected size (approximately 
108kDa) which was lacking from control embryos (data not shown). In addition, using an 







dominant-negative activity in COS-1 cells, indicating that this type of tag does not 







Figure 4. Images of a 3dpf zebrafish embryo generated by crossing the Tg(hsp70:Gal4) and
Tg(UAS:GFP-*&transgenic lines. Embryos were heat shocked at 37C for 2.5h at 1 and 2dpf. 
A. Transmitted light microscopy image showing representative embryo, indicating that 
transgenesis and heat shock treatment do not alter the morphology of zebrafish embryos. B.
Fluorescence microscopy image showing expression of the GFP-&
,
fluorescent signal is clearly present in the muscles, on the yolk sac and in the eyes. C. Larger 
magnification fluorescence microscopy image showing expression of GFP-&*	
,

















&-isoform or as an intrinsic transcription factor 
(i.e. independent  &), using a custom-designed Agilent 180k zebrafish microarray 
platform [63]. The Tg(hsp70:Gal4) line was crossed with the Tg(UAS:GFP-*& line. 
The resulting embryos were identified, upon heat shock, based on the observed 
fluorescence as either wild type (N) 	5 		  &-overexpressing 







beclomethasone (beclo) or vehicle for 6h at 3dpf. Thus, 4 groups were generated: 
NJ+	)NJ	)&J+	)&Jclo. Total RNA samples from 4 biological 
replicates (16 samples in total) were processed for the microarray study using a common 
reference design. Data were analyzed using Rosetta Resolver 7.2 software, setting 
signatures for significantly regulated probes at a p-value cutoff of p<10-5 and fold changes 
either >2 or <-2. Figure 5 gives a schematic overview of different microarray group












Microarray: 907 genes significantly changed
qPCR: 13 genes validated out of 13 tested
zGR intrinsic transcriptional activity
WT/vehicle vs zGR/vehicle
Microarray: 193 genes significantly changed
qPCR: 10 genes not validated out of 10 tested
zGR dominant-negative effect
WT/beclo vs zGR/beclo
Microarray: 29 genes significantly changed
qPCR: 8 genes not validated out of 8 tested
WT/vehicle vs WT/beclo
Figure 5. Schematic overview of microarray analysis and subsequent qPCR validation of beclo 
and zGR effects using a 180k zebrafish microarray platform. The Tg(hsp70:Gal4) line was 









beclo for 6h. Thus, 4 groups were generatNJ+	)NJ	)&J+	)&J	,
Total RNA samples were processed for transcriptome analysis by microarray. Results for beclo- as 
&-mediated effects on transcription were analyzed using Rosetta Resolver 7.2 software. 
Numbers of genes refer to annotated genes found to be significantly regulated at a p-value cutoff of 
p<10-5 and fold changes either >2 or <-2. Beclo regulation of genes is defined as significant up- or 




(  &     	
 - (or down-) regulation by beclo, and a 






(&fined as significant up- or down-regulation
  
 NJ+	 + &J+	  	*, Annotation and probe 
assignment was based on the Ensemble Gene ID codes (ENSDARG).
As a first step, we studied genes regulated upon beclo treatment in the wild type 
fish (WT/vehicle vs WT/beclo comparison). We identified 1805 probes corresponding to 
genes significantly upregulated by beclo treatment and 703 probes corresponding to 
downregulated ones. Of these 2508 total probes, 1592 could be attributed to an annotated 
gene (in total, 907 beclo-regulated genes). For 13 randomly chosen genes (10 up-regulated, 
3 down-regulated, Suppl. Table 1) which were represented in this cluster by at least two 
probes (enabling less false-positive discoveries), validation by qPCR was performed, and a 
significant effect of beclo treatment was confirmed for all genes tested (Fig. 6).
We, then, took the latter subset of probes representing beclo-regulated genes and 
compared the expression of these genes between the WT/beclo and the zGR/beclo group, 
in order to examine a dominant-
+ 	
  &, 4 :D  
 8D; 
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Figure 6. Validation by qPCR of the effect of beclo treatment on the expression of several genes 
identified as beclo-responsive in the microarray analysis. Expression rates of all genes were 
normalized to those of bactin1 and relative mRNA concentration values are the means ± s.e.m. of 
three independent experiments. A. Validation for genes identified as up-regulated by beclo 
treatment in the microarray study. Statistical analysis demonstrated that for all genes the mRNA 
expression was significantly higher in the beclo-treated group compared to the vehicle-treated one. 
B. Validation for genes identified as down-regulated by beclo treatment in the microarray study. 
Statistical analysis demonstrated that for all genes the mRNA expression was significantly lower in 
the beclo-treated group compared to the vehicle-treated one. Asterisks (*) correspond to a 
statistically significant difference between the beclo- and vehicle-treated group (p<0.05). These 
data confirm the effects of beclo treatment observed in the microarray analysis.
Within the cluster of 65 probes that indicated a dominant-negative activity of 
zGR 34 probes could not be attributed to an annotated gene. The other 31 probes could 
be attributed to 29 genes, since 27 genes were represented by one probe and only two 
genes (LOC100151204 and crybb2) by two probes (Table 1). This is not a result of these 
genes being represented by a low number of probes on the array, since only one of these 
27 annotated genes is represented by one probe on the 180k array whereas expression of 
the rest can be detected by multiple probes. LOC100151204 together with 7 randomly 
chosen genes from the pool of 29 annotated genes with putative dominant-negative 
regulation were used for validation of the microarray results by qPCR. In this validation, 
 	 
 +( ( 	
 & *
-negative effect on any of the genes 











able to regulate the expression of target genes, independent of zGR activity. For that 
  	* 
 NJ+	  &J+	    
 ;8






probes corresponding to down-regulated ones. 
Of these 481 regulated probes, 271 could not be attributed to an annotated gene. 
The other 210 probes corresponded to 193 genes. As expected, the GR gene itself was 





was detected with 12 probes. In addition, the hsp47 gene (5 probes) and the 
LOC100151204 and zgc: 111983 genes (2 probes) were represented by more than 1 probe 
(Table 1). The hsp47 and zgc: 111983 genes and eight randomly selected genes were used 
 +
, $) /%& (  
 +( ( 	
 & 	
  




WT/vehicle < WT/beclo WT/beclo > zGR/beclo
668 35 242
WT/vehicle > WT/beclo WT/beclo < zGR/beclo
BA
Figure 7. Analysis of the dominant-negative activity of zGR observed in the microarray. A.
Venn diagram depicting the pool of probes corresponding to transcripts upregulated in the 









group (white circle, 187 probes). The overlap between these pools (30 probes) represents 
transcripts which were significantly upregulated upon beclo treatment, reflecting a possible 
dominant-negative effect of zGR on transactivation properties of zGR. B. Venn diagram 
depicting the pool of probes corresponding to transcripts downregulated in the WT/beclo group 










probes). The overlap between these pools (35 probes) represents transcripts which were 





Differences between the clusters of beclo- -regulated genes
As presented previously, we were not able to verify by qPCR the regulation of genes due 

&+'2*
-negative or intrinsic transcriptional activity), whereas 
gene regulation due to beclo treatment was confirmed in all cases studied. This prompted 
us to further investigate differences between the clusters of beclo-  &-regulated 
genes. 
In our custom-made 180k microarray platform, the annotated (provided by 
ENSEMBL, www.ensembl.org) genes are represented by either one or multiple probes, 
with the largest number of them being represented by two probes (Table 1). Our analysis
revealed that approximately 33% of the beclo-regulated genes were represented within the 
cluster of beclo-regulated genes by more than one probe (Table 1), which is a dramatically 
higher percentage than that found in the subset of genes regulated by GR in a dominant-
negative way (7%), or as an intrinsic transcription factor (2% , Table 1). Limiting the 





-negative activity and 4 for 
& 
	 
	iptional activity), whereas still a significant number of beclo-
regulated genes (302 genes) would have been found in the array. The disadvantage of this 
analysis is that effects on genes that are represented by only one probe on the array (19% 
of genes represented on the 180k chip) are overlooked. Second, the p-values corresponding 
to the (significant) regulation of the individual probes were studied, and for each subset of 















negative activity), mainly show higher p-values, whereas beclo-regulated probes show a 
more even distribution over a wider range of p-values (Fig. 8A). Obviously, using a lower 
p-value as significance threshold would decrease the number of false positive results. For 




effect on only 11 probes (previously, that number was 65) and an intrinsic transcriptional 
activity on only 105 probes (previously, it was 481). In contrast, beclo treatment would 
significantly still affect 1809 probes (previously they were up to 2508). Lowering p-values 






regulated ones, since 72% of the beclo-affected probes previously regulated at a cutoff of 
p=10-5 are still regulated at a cutoff of p=10-10, $  &) 
 /+
 *
correspond to less than 17% for its dominant-negative effect and almost 22% for its 
intrinsic transcriptional activity. However, clusters deriving from a lower p-value could 




dominant-negative effect already two genes have been shown to be false positive hits by 






activity four genes have already been shown to be false positives by qPCR (Suppl. Table 
3).









Total no. probes 175975 2508 65 481
probes without
annotation
81534 916 34 271
probes with gene
annotation
94441 1592 31 210
Total (annotated) 
genes
23837 907 29 193
genes with 1 probe 4539 (19%) 605 (66.7%) 27 (93%) 189 (98%)
genes with 2 probes 4578 (19.2%) 127 (14%) 2 (7%) 2 (1%)
genes with 3 probes 3920 (16.4%) 78 (8.6%)
genes with 4 probes 3008 (12.6%) 47 (5.2%)
genes with 5 probes 2334 (9.8%) 21 (2.3%) 1 (0.5%)
genes with 6 probes 1728 (7.2%) 14 (1.5%)
genes with 7 probes 1238 (5.2%) 8 (0.9%)
genes with 8 probes 852 (3.6%) 1 (0.1)
genes with 9 probes 528 (2.2%) 2 (0.2%)
genes with 10 
probes
330 (1.4%) 4 (0.4%)
genes with 11 
probes
222 (0.9%)
genes with 12 
probes




Table 1: Overview of microarray results. Shown are the numbers of probes and annotated genes 
represented on the microarray and the numbers of probes and annotated genes showing significant 
regulation (p-value cutoff of 10-5 and fold changes either >2 or <-2). Annotation of probes was 
performed based on the Ensembl Gene ID codes (ENSDARG). Percentages correspond to the 
number of genes represented by a certain number of probes relative to the total number of 
annotated genes. The analysis shows that within the cluster of (beclo- &-) regulated probes 
the majority of corresponding annotated genes is represented by one probe, despite the fact that 
most of these can be detected by more than one probe on the array. Furthermore, approximately 
33% of beclo-regulated genes are represented by more than one probe, which is dramatically more 




In conclusion, a more stringent analysis of the microarray data (increasing 
significance threshold and excluding genes showing regulation for only one probe) 
dramatically decreases the size of the clusters of zGR-regulated genes, whereas it has a 
much smaller impact on the cluster of beclo-regulated ones. This suggests that the relative 
number of false-positives among the zGR-regulated genes is considerably larger than
among the beclo-regulated genes, which was confirmed by our qPCR validation that 










































Figure 8. Distribution of significantly regulated probes (cutoff set at p-value <10-5 and fold 
change of either >2 or <-2) from our microarray expression data analysis for beclo as well as 
&-mediated effects on transcription. A. Percentage (of the total number of regulated probes) of 
signature probes which fall into a certain range of p-values for beclo regulation (probes 
corresponding to transcripts up- or down-regulated in the WT/beclo group compared to the 
WT/vehicle group), & *
-negative effect (subset of beclo-regulated probes 
corresponding to transcripts up- or down-regulated in the zGR/beclo group compared to the WT 





( 2probes corresponding to 
transcripts up and down-regulated in tNJ+		*

&J+	,
For beclo regulation (white bars), there is a substantial probe presence over a wide range of p-
values even lower than 10-20, !	

) &-mediated effects (grey and black bars), their 
significantly regulated probes are mainly in p-values higher that 10-20. B. Percentage (based on the 





	&-regulated probes, fold changes mainly 




In the present study we have used the zebrafish as a model organism to investigate the 

(
&-isoform on gene transcription. We first looked at its 
dominant-negative effect on both transactivation and transrepression properties of the GR 















  &  & ' +	
, 
dominant-negative activity had already been observed in our laboratory using a 1:10 
&J&
[51], and recapitulates data obtained in similar reporter assays in which 
the human [15, 17, 52, 65] and mouse [53] &*
-negative effect at 1:10 
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literature on the human GR -isoform, since in most experimental approaches employing 






( dominant-negative activity on 
&





COS-7 cells [43].  In contrast, one study has demonstrated a specific dominant-negative 
effect on transrepression rather than transactivation using reporter assays [45] and a 
dominant-negative effect on the dex-	   34  !-B 
demonstrated by siRNA knockdown of hGR expression in human monocytes [33].
The reporter constructs used in our luciferase assays have simple promoters and are 




 &  '
 *
-negative properties on the 
&-induced transactivation of endogenous genes. From studies in human and mouse 
cell cultures there is a solid body of evidence that GR inhibits G&-induced 
transactivation of a number of endogenous genes, like MKP-1 in human monocytes [33] 
and BAL macrophages [23], myocilin and fibronectin in human trabecular meshwork eyes 
cells [32], CANT1, NEK2, TWSGI1, and LATS2 in Hela cells [40], and GILZ, PDK4, and 
G6Pase in mouse MEF cells [53]. 
In the present study, we started our investigation on endogenous genes by first 











(+'&2+ge ~260 fold higher 
at the mRNA level compared to wild type). We determined that zGR is expressed more 

 D 
*   
 	 
 &)  
 & -isoform as the 
predominant GR receptor at the mRNA level  
 	,  & 
ein has been 
shown to be more stable than GR in humans [66] and zebrafish [51], so it can be assumed 
that the higher zGR ' + 	* 
 & +   	 
 

mRNA level is translated to the protein level as well.





 &-induced transactivation of fkbp5 (a well-known 
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exhibit a general dominant-
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induced fkbp5 transcription, whereas a dominant-negative activity on other, mostly 












counteractive effect on oth&-target genes.
Previously, we had observed that 1dpf zebrafish embryos are responsive to GC 
treatment, as shown by an upregulation of the expression of  the GR target genes pepck,




&-isoform into 1-2 cell stage 
embryos. Like in the PAC2 cells, overexpression of 
&-isoform did not suppress 
&-mediated gene induction, as shown on all three genes tested (Fig. 3).
Subsequently, in order to get a genome-   +  
 &
transcriptional properties, we performed a transcriptome analysis upon &
overexpression in vivo. We generated the Tg(UAS:GFP-zGR) transgenic line that we 














results showed an effect of zGR overexpression on 481 probes (independent  &
activity), and 65 probes displayed a dominant-negative effect of zGR, out of a total of 
180,000 probes present on the array. However, after careful analysis of the microarray data 
we concluded that at least the vast majority of these data represent false positive results. 






remarkably different from those found for the cluster of probes showing regulation by 
beclo treatment (Fig. 8A and Table 1), raising questions about the confidence level of the 
results on zGR regulation. Indeed, using qPCR of a randomly selected set of genes 
showing regulation by zGR in the microarray we could not verify the effect of zGRon
any of the selected genes. Using qPCR on genes showing regulation by beclo could verify 
the results from the microarray on all selected genes, supporting the validity of our study. 
These results led us to suggest that the effects of zGR on transcription in our transgenic 
embryo model are absent. Combined with the negative results obtained in PAC2 cells and 
upon zGR mRNA injection in embryos, these data suggest that, if existing, any effect of 
zGR on transcription is probably limited to a very small subset of genes or highly specific 
for a certain tissue or condition, and is obscured in our experimental systems.
The lack of an effect of the GR -isoform in zebrafish presented in this study follows 
the trend of controver(+
		
&-isoform in humans. After more 
than 15 years of research, a consistent view on a possible dominant-negative activity on 
either transactivation or transrepression is still lacking. The observations on the intrinsic 
transcription factor activity of hGR [39, 40] have recently added more inconsistent data, 
since a large set of genes appeared to be oppositely regulated by hGR in different studies 
[14]. Our work on the functional role of zGR does not support a physiologically 
significant role for the GR -isoform, and we conclude that the effect of this type of GR 
splice variant on transcription is anything but universal or generic. Nevertheless, gene-,
cell type-, condition-, or species-specific effects can obviously not be ruled out, and these 
effects may explain the large inconsistencies in the literature on the GR -isoform.
Finally, C-terminal splice variants of nuclear receptors are widespread [68], and most 
of these splice variants have been shown to display dominant-negative activity on the 
transactivational properties of their canonical equivalent in reporter assays. However, the 
presented studies on the zGR -isoform demonstrate that dominant-negative activity 
observed in reporter assays is not necessarily followed by a similar effect in vivo. We 
93
 
suggest that splicing of a pre-mRNA into a messenger encoding an alternative splice 
variant could instead be a physiological way to downregulate the levels of the canonical 
receptor variant. In such a case, the GR -isoform does not have an active inhibitory role 
but it'
& available to mediate glucocorticoid signaling.
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 &) ;DD  

 &3$ * *
both PAC2-wt and PAC2-& 	 
((/%&&&*&3$
expression. Absolute amounts (± s.e.m.) of 
both transcripts were calculated based on 





7.08 ± 2.55fg per 500ng total RNA and 6.95 ±
2.63fg in PAC2-&,$&)
*&3$
concentration in PAC2-wt cells is 1.35 ±
0.34fg, per 500ng total RNA whereas in PAC2-
&)
*
	(T;,D;± 35.85fg. These results clearly demonstrate that in 
PAC2-wt cells, there is a more than 5-'	&*&3$	*
&
































Supplemental Figure 2. Dominant-negative activity of 
tagged and non-tagged zGR on transactivation 
analyzed by luciferase assays. COS-1 cells were 
transiently transfected with MMTV-luciferase reporter 
gene and & * together with either empty 
+	
) :DD &) :DD  DDD S4%-&
expression vectors and incubated with 100nM dex for 
24h. Relative luciferase activity values are the means ± 
s.e.m. of three independent experiments. The analysis
shows that in the presence of both tagged and non-
tagged &) &-mediated activation of luciferase 
gene is significantly suppressed. These data 




(  &  &-induced
transactivation in in vitro luciferase reporter assays. Asterisks (*) correspond to a statistical 
significance of p <0.001 as calculated by a Bonferroni’s multiple comparison test between 
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Chapter 5






In this thesis, we embarked on a series of experimental settings in order to explore the 
functional role of the glucocorticoid receptor (GR) pathway. We chose the zebrafish model 
system that in recent years has emerged as a versatile system for conducting biological 
research, due to the relative ease of genetic manipulation and handling, its transparency 
and resemblance of many physiological systems to those of mammals, such as the stress 
axis and the immune response.  Moreover, we opted to use microarray technology to 
analyze gene expression, in order to explore GR target genes at the whole transcriptome 
level. This way, we investigated the specificity and dynamics of transcriptional regulation 
by both the &- -isoform under different physiological conditions.





upon stimulation with synthetic glucocorticoids, affects the transcriptional rate of a large 
number of genes. Among them, many are known to be GR targets in mammals as well 
(e.g. fkbp5, pepck, il8, il1b, mmp9, $
() 	
+
  &  

immunosuppression, thereby recapitulating the well known anti-inflammatory effects of 
GC drug treatment.  
Our microarray analysis identified many molecular pathways to be affected by 
& 	
+
 such as metabolic, immune, and cell cycle-related signaling routes that 
could be used as a platform for further investigation of how exactly GCs control 
physiological systems in a whole organism. In our studies we also determined sets of genes 
to be upregulated (e.g. hsd11b2, fkbp5, agtxb, rhcgb) and downregulated by GCs (e.g. il8,
cyp2aa3, mmp9, mmp13a), which could constitute marker genes in more elaborate further 
studies, either in order to elucidate the transcriptional mechanisms of GR action or to 
perform screenings for novel GC drugs using the zebrafish as a model organism. 
In order to model local inflammation in zebrafish larvae at 3dpf (when only the 
innate immune system is active), we used a tail fin amputation assay. In this assay, it has 
been shown that within a few hours upon amputation a localized inflammatory response is 
generated, illustrated by migration of neutrophils and macrophages to the wound site. In 







migration of neutrophils, but not macrophages. In addition, large alterations in gene 
expression were found. Interestingly, it appeared that GC treatment suppressed virtually all 
amputation-induced gene regulation. Of all genes significantly upregulated by amputation, 
84% showed an attenuated upregulation in the presence of GCs. Furthermore, 92% of the 
genes significantly downregulated by amputation displayed an attenuation of this 
downregulation after GC treatment. Interestingly, GC treatment did not entirely block the 
transcriptional response to amputation for the vast majority of genes, but rather resulted in 
a decreased response. Thus, GC treatment appears to have a very general dampening effect
on alterations in gene expression induced by tail fin amputation. 
Gene ontology analysis showed that among the pathways that were induced upon 
amputation we found mainly immune-related signaling routes. GCs, apparently, attenuate 
all these inflammatory signaling cascades, ruling out specificity of GCs for specific 
pathways or immune-enhancing effects in this model. It could therefore be argued that the 
GR inhibits the activity of a ‘master switch’ of immune activation. An important role in 
this process could be for the AP-1 transcription factor complex, which is known to be an 
important transcription factor in the induction of the inflammatory response. The 
amputation-induced induction of 3 subunits of this transcription factor complex (fos, junb, 




physical interaction of GR and specific AP-1 subunits at the protein level, which also 
results in inhibition of AP-1 activity.
The overall dampening effect of GC treatment on amputation-induced changes in 
immune-related gene expression is in contrast with specific effects observed on leukocyte 
migration, which show a significant suppression in neutrophils, however no effect in 
macrophages. It could therefore be argued that the observed effects on gene expression do 
not necessarily reflect the alterations at the protein level or that the amputation-induced 
migration of leukocytes is mediated at a non-genomic level as well.
In further studies, the modulatory effects of GCs could be further explored using 
more physiological and cellular readouts (e.g. tissue regeneration, cell proliferation, 
apoptosis, phagocytosis), also in combination with specific GR knockdown or 
overexpression in particular tissues or cell types. Additionally, other types of immune 
challenges could be employed such as systemic bacterial infections as well as assessments 
at later stages of development when the adaptive immune system is present as well, so that 
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under basal conditions resulted in the alteration of the transcription rate of a different 
cluster of  










dexamethasone. In general, the first cluster of genes contains mainly genes involved in 







under no exogenous stimulation with GCs. A very interesting interplay between GR and 
p53 has been reported before, and the zebrafish could become a powerful in vivo model for 
studying this interaction at the whole organism level, for instance via looking at alterations 
in the level of apoptotic cell death during development. The finding of two distinct clusters 
of GR-regulated genes could open up new research lines concerning the biological 
significance of this receptor and its function under specific physiological conditions. It 
could be hypothesized that under resting conditions, the GR controls basal functions like 
the cell cycle to maintain homeostasis, whereas upon activation by increased GC levels 
(e.g. those resulting from the response to a stressful stimulus), the GR starts to regulate 
metabolic pathways in order to restore homeostasis. Further examination of the 













*	*	*&-mediated transcription under various 
physiological conditions. 
Finally, we were also interested in the biological significance of the GR -isoform. 
In humans this splice variant has been shown to act as a dominant-negative inhibitor of 
&  
   
 





However, there is a lot of controversy regarding its low expression level and its effects on 

	
,    '  & -isoform and hence, it could be an 
interesting model to elucidate the role of this receptor isoform in vivo.
In the present work, using ove'  & 
 >	
  &
mRNA, and through the generation of a transgenic fish, we aimed to unravel its function 
with respect to the regulation of gene expression. First we studied whether zGR acts as a 
dominant-negative inhibitor of &. Our data do not support such a role, since only 1 








Second, we studied wh
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the canonical GR 	-isoform in order to render a cell less responsive to GCs. 
Surprisingly however, upon injection of a morpholino altering the splice pattern of 
zGR pre-*&3$
	&production, we found more genes of which the 
expression was altered than after treatment with a morpholino that only resulted in 
	 & ', $





regulated by the two morpholinos there was a large cluster of genes that was exclusively 













a result of a more efficient 5	5&(
*,
In conclusion, the zebrafish model system with its opportunities for genetic 
manipulation constitutes a versatile in vivo system, in order to further explore GR gene 
function and signaling. Our exploratory studies provided us a set of GR regulated genes to 
be used for future investigation of the mechanisms of GR action, interaction and biological 
significance, regarding GC regulation of various biological processes (e.g. development, 

































The glucocorticoid receptor (GR) signaling pathway is essential for the survival and 
wellbeing of most vertebrate organisms and in addition, it significantly contributes in 
combating inflammation (reviewed in Chapter 1). Hence, the scope of the present thesis 
was to elucidate the biological significance and action of the glucocorticoid receptor by 
means of genetic manipulation and stimulation with synthetic glucocorticoids (GCs). As a 
model organism, we employed the zebrafish, that allows fine genetic, molecular and 
cellular experimental approaches and as our main readout we used transcriptome analysis, 
since the GR is a transcription factor. Our aim was also to further characterize the function 
of this versatile signaling cascade in zebrafish, in order to establish this animal model as a 
valid system for detailed as well as high throughput research on GR.
In chapter 2, we explored the role of the &-*2&) with respect to 
modulating the inflammatory response to a wound injury. For that reason, a tail fin 
amputation assay was employed in 3-day-old zebrafish larvae which were subsequently 
treated with the synthetic GC beclomethasone. Amputation elicited a migratory behavior 
towards the wound site for both macrophages and neutrophils as well as induction of 
several immune-related signaling routes. Using cell imaging as well as whole transriptome 
analysis, we studied the GC effect on the cellular trafficking of leukocytes as well as on 
the transcriptional rate of genes involved in molecular networks altered due to amputation. 
Our results show that beclomethasone treatment of amputated larvae attenuated the 
migratory behavior of neutrophils, but not of macrophages. Additionally, GC treatment 
had a very general dampening effect on the induction of gene expression upon amputation, 
without any apparent specificity for particular pathways. These results show that the 
zebrafish larva model of tail fin amputation and beclomethasone treatment recapitulates 
the anti-inflammatory GC effects, thus providing a reliable model system to further 








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vely). Zebrafish embryos were injected with two 
splice-blocking morpholinos 2  
 5	5  
 &  &) 
another targeting the alternative splicing of the zGR pre-*&3$  +  
 & -
*  
 & *&3$ 2
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, <*(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were treated with the synthetic GC dexamethasone and transcriptome analysis was 
performed using microarray technology. This experimental design allowed us to answer 3 
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dexamethasone treatment. In general, the first cluster mainly contains cell-cycle related 









&,Nevertheless)&	d have an intrinsic transcriptional activity that 
would require high expression levels of this splice variant.
111
 
In chapter 4, we embarked on a series of experimental approaches allowing us to elucidate 
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transcriptional activity, meaning independent of zG&, W +' &
transiently by cell transfections using a & expression plasmid. Luciferase reporter 






&,6+r, no such effect was observed in 
zebrafish PAC2 cells using the induction of the fkbp5 gene as readout. In addition, upon 
&*&3$>	
*()dominant-negative effect was observed 

&-induced transactivation of the fkbp5, pepck and +  genes. Subsequently, 
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analysis by microarray and subsequent qPCR validation using this line did not reveal any 
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zebrafish GR -isoform does not have a regulatory role in transcription and that splicing of 
the GR pre-mRNA into a messenger encoding an alternative splice variant could instead 
represent a physiological mechanism to downregulate the levels of the canonical receptor 
variant. 
In chapter 5, results from all three experimental chapters were discussed collectively in 
order to draw conclusions about the validity of zebrafish as a model system for GC 
research and, most importantly, the role and function of both zGR splice variants. Our 
work showed that the zebrafish is a reliable system to study the GR signaling pathway 
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transactivation of genes and immunosuppressive activity. Furthermore, our whole 
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dependent gene expression regulation under different conditions. These data can further be 
investigated in more detail, in order to study the biological significance and molecular 
properties and interactions of this receptor with respect to specific physiological settings. 
For instance, different inflammatory responses could easily be modeled in zebrafish, and 
	*
+ (  &-mediated regulation of the immune response could be 

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Signaling gemedieerd door de glucocorticoid receptor is essentieel voor het overleven en 
welzijn van de meeste gewervelde dieren, en het draagt bij aan het bestrijden van 
ontstekingen (voor een review zie hoofdstuk 1). De focus van dit proefschrift is dan ook 
om de biologische significantie en de werking van de GR op te helderen door middel van 
genetische manipulatie en stimulatie met synthetische glucocorticoïden (GCs). Als 
modelsysteem hebben we de zebravis gebruikt, die het mogelijk maakt om nauwgezette 
genetische, moleculair- en celbiologische experimenten uit te voeren. Als belangrijkste 
uitleessysteem hebben we transcriptoomanalyse gebruikt, omdat de GR een 
transcriptiefactor is. Het doel van het onderzoek was verder om de functie van deze 
veelzijdige signaalcascade te karakteriseren in zebravis, om dit diermodel op te zetten als 
systeem om zowel zeer gedetailleerd als high-throughput GR onderzoek te doen.
In hoofdstuk 2 hebben we de rol van de zebravis GR -isoform (zGR) onderzocht in de 
modulatie van de immuunrespons na een verwonding. Hiervoor hebben we het 
staartvinamputatie-model gebruikt in drie dagen oude zebravis larven die na de amputatie 
met het synthetische GC beclomethason werden behandeld. Amputatie veroorzaakte 
migratiegedrag naar de plaats van verwonding voor neutrofielen en macrofagen, en 
veroorzaakte daarnaast de activatie van een groot aantal immuun-gerelateerde 
signaalroutes. Met behulp van microscopische en transcriptoomanalyse hebben we het GC 
effect op leukocytmigratie onderzocht en de transcriptionele activiteit van genen 
bestudeerd die een rol spelen in de door amputatie veranderde moleculaire netwerken. 
Onze resultaten laten zien dat behandeling van geamputeerde larven met beclomethason de 
migratie van neutrofielen remt, maar niet die van macrofagen. Daarnaast heeft GC 
behandeling een zeer algemeen dempend effect op de inductie van genexpressie na 
amputatie, zonder enige zichtbare specificiteit voor bepaalde signaalroutes. Deze resultaten 
laten zien dat het model van staartvin amputatie in zebravis larven gecombineerd met 
beclomethasonbehandeling goed de ontstekingsremmende werking van GCs nabootst, en 
dus een betrouwbaar modelsysteem is voor verder onderzoek naar de moleculaire 
mechanismen van GC signaling.
In hoofdstuk 3 hebben we de specificiteit en functie van de zebravis GR - en -isoform 
(zGRen zGR) onderzocht. Zebravisembryo’s werden geïnjecteerd met twee morfolino’s 
die splice-sites blokkeerden (één die zowel zGR als zGR expressie omlaag reguleerde 
en één die de splice-site die to zGR expressie leidt blokkeerde) en met zGR mRNA (wat 
tot zGR overexpressie leidt). Embryo’s werden behandeld met het synthetische GC 
dexamethason en vervolgens werd transcriptoomanalyse uitgevoerd met behulp van 
microarray technologie. Dit experiment maakte het mogelijk om drie vragen te 
beantwoorden. Ten eerste, welke specifieke genen worden door zGR gereguleerd onder 
specifieke fysiologische condities? Ten tweede, heeft zGR een dominant-negatieve 
werking heeft op de transcriptionele activiteit van zGR? Ten derde, welke genen worden 
specifiek gereguleerd door een mogelijk intrinsieke transcriptionele activiteit van zGR?
Onze transcriptoomanalyse liet twee verschillende clusters van genen zien die werden 
gereguleerd door zGR. Eén cluster, dat werd gereguleerd onder basale condities, en een 
dat werd gereguleerd na zGR activatie door beclomethasonbehandeling. In het algemeen 
bevat het eerste cluster vooral genen die betrokken zijn bij de celcyclus terwijl het tweede 
cluster vooral genen bevat die een spelen in het metabolisme. Verder vonden we geen 
bewijs voor een dominant-negatieve werking van zGR op de transcriptionele activiteit 
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van zGR. Een intrinsieke transcriptionele activiteit van zGR kunnen we op basis van 
deze resultaten niet uitsluiten, al zou hiervoor wel een hoog expressieniveau van deze 
splice variant nodig zijn. 
In hoofdstuk 4 hebben we een serie van experimentele benaderingen gekozen die het ons 
mogelijk maakte om de biologische significantie van de zGR -isoform te bestuderen. In 
het bijzonder waren we geïnteresseerd in twee vragen. Ten eerste, veroorzaakt zGR
dominant-negatieve inhibitie op de transcriptionele activiteit van zGR? Ten tweede, laat 
zGR intrinsieke transcriptionele activiteit zien, dus onafhankelijk van zGR? We hebben
zGR transiënt tot overexpressie gebracht door cellen te transfecteren met een zGR
expressievector. Luciferase reporter assays op getransfecteerde COS-1 cellen lieten een 
dominant-negatief effect zien van zGR op de trasncriptionele activiteit van zGR. Echter, 
dit effect was niet te zien in zebravis PAC2 cellen, wanneer we gebruik maakten van de 
inductie van het fkbp5 gen als uitleessysteem. Daarnaast zagen we geen dominant-negatief 
effect van zGR op de zGR-geïnduceerde transactivatie van het fkbp5, pepck en nfkbiaa
gen. Vervolgens hebben we een transgene zebravislijn vervaardigd met induceerbare 
overexpressie van zGR. Gebruik makend van deze lijn werd transcriptoomanalyse met 
behulp van microarrays en qPCR validatie gedaan, en geen effect van zGR overexpressie 
kon worden gedetecteerd (noch de dominant-negatieve activiteit, noch de intrinsieke 
transcriptionele activiteit). Door deze resultaten kunnen we stellen dat de zebravis GR-
isoform geen regulerende rol heeft op transcriptie en dat splicing van het GR pre-mRNA 
tot een mRNA dat codeert voor zGR een fysiologisch mechanisme zou kunnen zijn dat er 
enkel op gericht is de expressie van de klassieke GR -isoform omlaag te reguleren.
In hoofdstuk 5 worden de resultaten van de drie voorgaande hoofdstukken bediscussieerd 
om vervolgens conclusies te trekken over de validiteit van het zebravis modelsysteem voor 
GC onderzoek en, nog belangrijker, de rol en activiteit van beide zGR splice varianten. 
Ons werk laat zien dat de zebravis een betrouwbaar systeem is om de GR signaalroute te 
bestuderen, omdat in dit modelorganisme klassieke effecten van GR activatie nagebootst 
kunnen worden als transactivatie van specifieke genen en de immuunsuppressieve 
werking. Verder heeft de transcriptoomanalyse, uitgevoerd op een compleet, intact 
organisme, een schat aan informatie opgeleverd over GR-afhankelijke genexpressie onder 
verschillende fysiologische condities. Deze gegevens kunnen verder en in meer detail 
worden bestudeerd, om de biologische significantie, moleculaire eigenschappen en 
interacties van deze receptor te bestuderen in relatie tot specifieke fysiologische 
omstandigheden. Zo kunnen bijvoorbeeld verschillende vormen van ontstekingsreacties 
makkelijk worden gemodelleerd in +) * ++  &-gemedieerde 
regulatie van deze reactie geanalyseerd. Wat betreft de biologische functie van zGR
vinden we in onze data geen bewijs voor een dominant-negatieve rol van zGR op de 
transcriptionele activiteit van zGR, terwijl een intrinsieke transcriptionele activiteit niet 
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